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Doxorubicin (DOX) has been used for decades to treat hematopoietic and solid tumors, 
although, in a subset of cancer survivors, it causes cardiotoxicity decades after treatment. 
The mechanisms of anthracycline-induced cardiotoxicity (ACT) are still incompletely 
understood. Induced pluripotent stem cells (iPSCs)-derived cardiomyocytes have become a 
valuable tool to study hereditary and structural cardiac conditions in vitro. A former study 
from our group showed that iPSC-derived cardiomyocytes (iPSC-CMs) from lymphoma 
patients with ACT were continuously more sensitive to DOX toxicity, demonstrating 
disorganized myofilament structure and altered calcium handling along with increased cell 
death and reactive oxygen species (ROS) production compared to control iPSC-CMs. 
The aims of this study are to (1) analyze the cellular resorption and distribution of DOX, (2) 
assess its impact on mRNA translation, (3) address an ACT-associated single-nucleotide 
polymorphism (SNP) (rs13058338 in the RAC2 gene) in ACT disease progression, (4) test a 
potential treatment option with TERT overexpression, and finally, (5) distinguish between 
ACT and unspecific effects of DOX in human cardiomyocytes. To this end, iPSCs from ACT- 
and dilated cardiomyopathy (DCM)-patients as well as control iPSC lines were differentiated 
into three-month-old iPSC-CMs and treated with DOX to model the effects of the drug 
exposure on human cardiomyocytes. In the first part of the study, the cellular resorption and 
retention of DOX in iPSC-CMs was investigated using high-performance liquid 
chromatography (HPLC) and positive correlations between DOX treatment time, treatment 
concentration and intracellular DOX levels were found. Intracellular DOX levels were 
consistently higher in ACT-iPSC-CMs compared to control iPSC-CMs and DOX remained 
longer in ACT-iPSC-CMs after treatment compared to control iPSC-CMs. In summary, these 
experiments suggested little regulation of DOX uptake or efflux in general. In the next 
chapter, the impact of DOX on mRNA translation was tested using the puromycin-protein 
incorporation assay. These data showed a significant decrease in translation down to 80% 
after DOX treatment in all tested iPSC-CMs as compared to untreated controls. In the third 
part of this work, the SNP rs13058338 was successfully edited in the RAC2 gene in an ACT 
patient iPSC line and heterozygous and homozygous isogenic gene-corrected ACT-iPSC-
lines were established. The established, gene-edited iPSC lines will enable us to unravel the 
RAC2-SNP-related molecular contributions to ACT predisposition by testing the susceptibility 
to DOX-induced cardiotoxicity in isogenic ACT-iPSC-CMs. In order to analyze the 
contribution of cardiomyocyte-specific telomere lengths in ACT, quantitative polymerase 
chain reaction (qPCR) and quantitative fluorescent in situ hybridization (qFISH) experiments 
were performed. It was found that telomeres are shorter in iPSC-CMs compared to iPSCs 




(TERT) activity in cardioprotection was assessed with TERT overexpression in iPSC-CMs 
using adeno-associated-virus 6 (AAV6) vectors. We did not find measurable TERT-induced 
effects in the tested ACT-iPSC-CMs regarding apoptosis rates (Annexin V/PI kit for flow 
cytometry) or extracellular ROS production (Amplex red) after DOX treatment. Finally, DCM-
iPSC-CMs were included in the study to identify differences in disease mechanisms that are 
common in ACT-specific myocardial processes. Therefore, DOX-treated DCM-iPSC-CMs 
were tested for cell volume and sarcomeric regularity. DOX treatment had differential impacts 
on sarcomeric integrity of iPSC-CMs from the DCM cohort as compared to the ACT cohort, 
mainly due to highly deteriorated DCM-iPSC-CMs before DOX treatment. Control iPSC-CMs 
from the DCM cohort showed a similar decrease in sarcomeric integrity as control iPSC-CMs 
from the ACT cohort.  
In conclusion, this thesis shows that ACT-iPSC-CMs can be used to determine subcellular 
DOX levels and, in addition, allows assessing the impact of this anthracycline on cellular 
processes such as mRNA translation. iPSC-CMs from ACT patients are more susceptible to 
the detrimental effects of DOX treatment than iPSC-CMs from controls or other cardiac 
disease such as DCM. This tool will allow for identifying the underlying genetic basis and 






2.1. Anthracycline-induced cardiotoxicity (ACT) 
2.1.1. Clinical implications 
The anthracycline drug doxorubicin (DOX) was first isolated in 1960 and tested in anti-cancer 
treatment soon afterward (Camerino and Palamidessi, 1960; Tan et al., 1967; Arcamone et 
al., 1969). Anthracycline-induced cardiotoxicity (ACT) was first described in 1971 (Middleman 
et al., 1971). Although it has now been known for decades that DOX can trigger 
cardiotoxicity, its outstanding efficacy against a broad range of solid and hematopoietic 
cancers makes it difficult to abandon its use. Currently, it is administered to 32% of breast 
cancer patients (Giordano et al., 2012), 57 – 70% of elderly lymphoma patients (Nabhan et 
al., 2015; Chihara et al., 2016), and almost 60% of pediatric cancer patients (van Dalen et 
al., 2014). In children younger than three years of age, the drug clearance is lower, which 
should be considered when calculating treatment plans (Völler et al., 2015). Clinical 
symptoms of ACT can occur acutely with DOX treatment or after treatment with refractory 
periods of several years. Diagnosis of ACT is based on arrhythmia, aberrant beating 
frequencies of the heart, decrease in left ventricular ejection fraction (LVEF), and fractional 
shortening (Magdy et al., 2016).  
After it became evident that the risk of ACT rises with increasing doses of DOX, the life-long 
cumulative dose of DOX was limited to 500 mg/m2 (Lefrak et al., 1973; von Hoff et al., 1979; 
Swain et al., 1997). However, a decline in LVEF has been described with cumulative doses 
of as little as 150 mg/m2 (Plana et al., 2014; Henriksen, 2018). More recent studies suggest 
that the incidence of ACT is still around 5 – 9%, with up to 18% of DOX-treated patients 
showing subclinical symptoms (Swain et al., 2003; Lotrionte et al., 2013; Cardinale et al., 
2015). 
ACT has been distinguished into two categories: an acute, reversible form with no 
morphologic changes in cardiac tissue, and a chronic, irreversible form, which shows 
myofibril loss and swelling of mitochondria, among other pathologies (Minotti et al., 2004). 
Recent, prospective studies by the Cardinale and Groarke labs are changing our 
understanding of ACT (Cardinale et al., 2015; Groarke and Nohria, 2015) as they suggested 
a single progressing disease. It has been reported that acute ACT occurs only during or 
within hours of DOX application, while the chronic form surfaces years or even decades after 
treatment (Steinherz, 1991). With the latest study results, it is conceivable that “chronic” 
cases could be detected shortly after treatment by assessing subclinical symptoms (Chung 
and Youn, 2016). Early diagnosis of ACT paired with appropriate treatment might lower the 
incidence of irreversible congestive heart failure (CHF) associated with the administration of 




2.1.2. Molecular mechanisms 
DOX is applied in cancer treatment because it reliably arrests cancer cell growth and leads to 
apoptosis (recently reviewed by Cai et al., 2019). The exact mechanisms of the anti-
neoplastic effects of DOX are still unclear; however, DOX is known to intercalate with DNA, 
produce double-strand breaks (DSBs), damage mitochondria, and induce elevated levels of 
reactive oxygen species (ROS) (Minotti et al., 2004). It is assumed that the properties that 
make DOX an effective anti-cancer drug are also responsible for its adverse effects on the 
heart. 
2.1.2.1. Elevated ROS levels 
DOX-induced damage through elevated ROS levels has been established as a key driver of 
ACT development for several decades (Doroshow et al., 1980; Nozaki et al., 2004; Ichihara 
et al., 2007). ROS-producing DOX-metal complexes were already described in the 1980s 
(Demant and Jensen, 1983). The so-called redox cycling is catalyzed by flavoproteins and 
produces superoxide (Doroshow, 1983; Davies and Doroshow, 1986; Hrdina et al., 2000). If 
the DOX complex is formed with Fe(III), nicotinamide adenine dinucleotide phosphate 
(NADPH) cytochrome P450 reductases and thiols facilitate the reduction to Fe(II) under 
production of ROS (Xu et al., 2005). However, ROS-producing redox cycling might not even 
be the most damaging result of the interaction between DOX and iron. DOX also inactivates 
iron-regulatory proteins (Ichikawa et al., 2014), leading to disturbed iron homeostasis and 
excessive iron accumulation in cardiomyocytes (CMs) (Ghigo et al., 2016). Even if iron is not 
directly part of the complex, it can catalyze reactions like Fenton reactions or Haber-Weiss 
reactions, which result in highly reactive hydroxyl radicals (Kaiserová et al., 2007). 
Today it is known that small amounts of ROS are not merely a side product of cellular 
processes, but act in physiological and pathological cell signaling (Hancock et al., 2001; 
Dworakowski et al., 2006; Brieger et al., 2012; Hafstad et al., 2013). Elevated ROS levels, 
when not confined to specific cell compartments, lead to oxidative stress which in turn can 
cause adverse effects including DNA damage, senescence, and cell death (Cappetta et al., 
2017). 
2.1.2.2. Mitochondrial damage 
The most damaging effect of DOX on the heart is likely its detrimental effects on 
mitochondria (Lebrecht and Walker, 2007). In CMs there are mitochondria high densities and 
are crucial for sustained production of ATP to enable contraction. DOX binds to cardiolipin in 
the inner mitochondrial membrane, which results in high DOX concentrations in the 
mitochondrial vicinity (Goormaghtigh and Ruysschaert, 1984; Nicolay et al., 1984; 
Goormaghtigh et al., 1990; Aryal and Rao, 2016). It also intercalates with mitochondrial DNA 




interferes with the electron transport chain, disrupts mitochondrial membranes, and therefore 
induces mitochondrial ROS production (Gosalvez et al., 1974; Ichikawa et al., 2014). 
2.1.2.3. DNA damage 
DOX damages DNA in two ways. The drug intercalates directly into DNA by hydrogen 
bonding its amino group with cytosines (Agudelo et al., 2014). In addition, DOX binds to 
topoisomerase II (TOP2) and forms a TOP2-DOX-DNA complex (Lyu et al., 2007). TOP2 is a 
highly conserved enzyme, which introduces double-strand breaks to relax supercoiled DNA. 
There are two isoenzymes: TOP2α and TOP2β. DOX forms complexes with both isoforms, 
where it stabilizes an intermediate reaction complex, in which the cleaved DNA cannot be 
resealed (Kellner et al., 2002), which leads to increased cellular stress, growth arrest, and 
apoptosis (Tewey et al., 1984; Hong et al., 1990; Chen et al., 2012c). TOP2α is highly 
expressed in proliferating cells and is crucial for chromosomal segregation, which makes it a 
worthwhile target in anti-cancer therapy (Azarova et al., 2007). TOP2β is mainly present in 
quiescent cells, like cardiomyocytes, where it is constitutively expressed (Tewey et al., 1984; 
Zhang et al., 2012). TOP2β knockout mice were partially protected from DOX-induced 
cardiotoxicity, highlighting the importance of this process in the development of ACT and 
making it a potential target for therapy (Zhang et al., 2013; Vejpongsa and Yeh, 2014). 
2.1.2.4. Protein degradation 
DOX reversibly binds to proteasomes and serves as an allosteric, non-competitive inhibitor, 
leading to the accumulation of ubiquitinated proteins (Minotti et al., 2004). DOX induces 
autophagy, but it also blocks the completion of the process causing an accumulation of 
autophagosomes (Li et al., 2016; Koleini and Kardami, 2017). These findings indicate that 
DOX severely limits cellular degradation and recycling processes. Taken together, there are 
multiple ways in which DOX inflicts oxidative stress, interrupts physiological rates of 
degradation, and causes cellular damage.  
2.1.3. Risk factors 
In order to prevent ACT, clinical studies have sought to find risk factors that can predict 
susceptibility to the development of the disease (Wojnowski et al., 2005; Reichwagen et al., 
2015; Leong et al., 2017). Among accepted risk factors are previous cardiac diseases 
including hypertension and coronary artery disease (Qin et al., 2015), African-American 
ethnicity, and very young or old age (Lipshultz et al., 1995; Lotrionte et al., 2013; Wang et al., 
2018). Female gender is associated with higher risk in pediatric cancer patients (Silber et al., 
1993; Lipshultz et al., 1995; Meiners et al., 2018). In adult patients, it is unclear whether 
gender influences the risk (Meiners et al., 2018). Other risk factors include positive epidermal 
growth factor receptor 2 status or type II diabetes, where the latter was identified as risk 
factor for late-onset ACT (Qin et al., 2015). However, the high interindividual variability in the 




Some patients tolerate high amounts of DOX, whereas others without any previous risk 
factors suffer from ACT after comparatively low doses. Recent clinical studies may narrow 
down the list of potential genetic causes (Blanco et al., 2012; Visscher et al., 2015; Vulsteke 
et al., 2015). However, they cannot reveal underlying mechanisms and, hence, cannot prove 
the involvement of the identified genes. It is of utmost importance to identify the involved 
mechanism, so the detrimental effects of DOX can be exploited for cancer treatment while 
other organs like the heart are protected. 
2.1.4. NADPH oxidases 
Among the genetic factors that were associated with the occurrence of ACT are single- 
nucleotide polymorphisms (SNPs) in genes encoding for subunits of the NADPH oxidase 2 
(Nox2) (Wojnowski et al., 2005; Reichwagen et al., 2015; Vulsteke et al., 2015; Leong et al., 
2017). The family of NADPH oxidases (Noxes) was first studied in neutrophils, where the 
enzyme complex is involved in the respiratory burst of phagocytes (Rossi and Zatti, 1964). It 
was the first time that a protein complex was identified, whose primary function was to 
generate ROS, rather than producing it as a side product. Noxes consist of six 
transmembrane domains and a cytoplasmic NADPH-binding site at the COOH terminus 
(Brandes et al., 2014a). In the proximity of the most COOH-terminal transmembrane domain 
is a flavin adenine dinucleotide (FAD)-binding region. Furthermore, each Nox complex has 
four highly conserved heme-binding histidines, two of which are located in the third and two 
others in the fifth transmembrane domain. In this way, Noxes can transport single electrons 
from NADPH via FAD, the first heme, and subsequently via the second heme to oxygen 
(Cave et al., 2006; Brandes et al., 2014b). 
The family members Nox4, DUOX1, and DUOX2 produce H2O2, whereas Nox1, Nox2, Nox3, 
and Nox5 produce superoxide (Brandes et al., 2014a). Today, it is known that Nox 
expression and activity are not restricted to phagocytes. Nox1, Nox2, Nox4, and Nox5 are 
expressed in cardiac cells where they are involved in the regulation of gene expression, cell 
growth and senescence, differentiation and proliferation, as well as oxygen sensing (Petry et 
al., 2006; Bedard and Krause, 2007). In postmitotic tissues such as the heart, Nox-derived 
ROS can act as signaling molecules to induce regeneration after injury (Hervera et al., 2019). 
Nox2 and Nox4 are the predominately expressed Nox types in cardiomycytes and have been 
studied extensively (Ambasta et al., 2004; Pendyala and Natarajan, 2010; Zhang et al., 
2013). While calcium activates Nox5, DUOX1, and DUOX2 (Dupuy et al., 1999; Kawahara et 
al., 2011), Nox4 is constitutively active and therefore regulated through expression (Martyn et 
al., 2006; Serrander et al., 2007). Nox4 is a membrane-bound protein complex, consisting of 
the catalytic subunit of Nox4 and p22phox. Nox1, Nox2, and Nox3 share some common 
cytosolic activators including the small GTPase Rac (Hancock et al., 2001; Bokoch and 




(Brandes et al., 2014a). NOX2 gene expression is mediated through the transcription factors 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 
1, which are, in turn, influenced by the redox state of the cell (Pendyala and Natarajan, 
2010). G-protein-coupled receptor agonists, e.g., endothelin-1, angiotensin II, cytokines, and 
growth factors (Santos et al., 2011) activate Nox2. This process is tightly regulated and 
includes the Nox2 subunits p40phox, p47phox, and p67phox (Bedard and Krause, 2007; van 
der Vliet, 2008). The component p47phox is activated through multiple phosphorylations, 
which is initiated through mitogen-activated protein kinase 3 (MAPK 3), p38 MAPK, the 
serine/threonine kinase PAK1, and AKT signaling (El Benna et al., 1996; Groemping et al., 
2003; Groemping and Rittinger, 2005; Raad et al., 2009). Nox2 activation is part of ROS 
signaling cascades, and as such, it is induced by tyrosine kinase receptors and MAPKs, as 
well as by ligands including tumor necrosis factor, angiotensin II, or epidermal growth factor 
(Holmström and Finkel, 2014; Park et al., 2016). Overactivation of Nox2 by DOX through 
aberrant signaling pathways increases intracellular ROS production and worsens oxidative 
stress (Angsutararux et al., 2015). SNPs that alter the function of this complex interplay 
might drive ACT development and cause a CHF phenotype. In CHF due to ACT, Nox2 is 
involved in apoptosis of CMs and cardiac fibrosis (Johar et al., 2006; Hayashi et al., 2008; 
Gilleron et al., 2009). In a mouse model, Nox2-derived ROS contributed to ACT (Zhao et al., 
2010). The authors found contractile dysfunction, myocardial atrophy, apoptosis and 
interstitial fibrosis, which was also observed in vitro (Gilleron et al., 2009; Ma et al., 2013). 
Nox4 is a membrane-bound protein complex, consisting of the catalytic subunit of Nox4 and 
p22phox. While Nox2 activity is often associated with poorer outcome in cardiac conditions, 
the activity of Nox4 has been described as cardioprotective (Zhang et al., 2013). 
2.1.5. Prevention 
The risk factors mentioned above are not sufficient to develop safe individual DOX treatment 
plans for cancer patients. However, there have been other efforts to reduce the risk of 
cardiotoxicity. Some anthracyclines, including epirubicin, are less harmful than DOX but are 
usually administered with higher accumulative doses (Table 2-1). A meta-study of five 
randomized controlled trials, based on 1036 patients, found no benefit in the use of epirubicin 
regarding cardiotoxicity compared to DOX (van Dalen et al., 2010). Idarubicin, another 





Anthracycline Relative cardiotoxicity Incidence of LVSD/CHF 
Doxorubicin 1 3-5% at 400 mg/m2 
Epirubicin 0.7 0.9-11.4% at 900 mg/m2 
Idarubicin 0.53 5% at 150 mg/m2 
Liposomal doxorubicin 0.5 2% at 900 mg/m2 
Data	from	McGowan	et	al.,	2017.	
A new generation of analogs of DOX has been synthesized, where a formamidine system 
replaced the amino group in daunosamine. Tested derivatives demonstrated better anti-
cancer properties when compared with the conventional DOX and showed less cardiotoxicity 
in murine in vitro studies (Wasowska et al., 2005; Denel-Bobrowska and Marczak, 2017).  
The manner of DOX administration affects the severity of side effects on the heart. 
Optimizing the drug administration can alleviate side effects without imparing anti-tumor 
efficacy. A clinical trial showed that prolonged infusion of DOX with reduced flow limits the 
peak plasma levels of DOX leading to reduced cellular drug uptake and a smaller risk of 
cardiotoxicity while maintaining efficacy against cancer cells (Legha et al., 1982). 
Mathematical models confirmed that prolonged infusion times are advantageous over bolus 
injection and liposomal delivery (El-Kareh and Secomb, 2000). In the meantime, novel 
developments, including galactosylated micelles and inducible liposomes, have improved the 
performance of enveloped drug delivery (Kneidl et al., 2014; Yu et al., 2014). A more recent 
meta-study concludes that in adults with a solid tumor, liposomal-encapsulated DOX is 
favorable over free DOX in terms of cardioprotection (van Dalen et al., 2014). 
Thermosensitive liposomes for DOX delivery increased DOX concentrations in the tumor 
vicinity, while reducing peak plasma concentrations (Abraham et al., 2005; Riccardi et al., 
2013; Xing et al., 2015; Motamarry et al., 2017). In dogs and pigs, peak and overall drug 
concentrations in the cardiac muscle were 30–40% lower after liposomal DOX treatment 
compared to the free DOX (Kanter et al., 1993; Gyöngyösi et al., 2019). Porcine studies with 
lyso-thermosensitive liposomal doxorubicin for the treatment of bladder cancer showed 
enhanced drug delivery to the target tissue and reduced burden on healthy tissues (Mikhail 
et al., 2017). Numerous phase 1 trials have shown that this approach is also applicable in a 
human setting. The clearance of liposomal DOX was more than five-fold lower, and the 
volume of distribution was approximately 10- to 15-fold lower compared to DOX alone 
(Swenson et al., 2003; Mross et al., 2004). Another single-center, phase 1 trial showed that 
ultrasound-triggered liposomes increase the intratumoral DOX concentrations on average by 
3.7 times compared to standard DOX (Lyon et al., 2018). Although liposomal DOX did not 




DNA damage resistance (Gyöngyösi et al., 2019). In summary, optimizing DOX 
administration through reduced flow rates, encapsulation, or through highly targeted delivery, 
lowers the risk of side effects on the heart. 
To specifically reduce the risk of cardiac damage, DOX treatment has been complemented 
with classic cardioprotective drugs such as dexrazoxane or angiotensin-converting enzyme-
inhibitor, angiotensin-receptor blockers (ARB), and beta-blockers (Vejpongsa and Yeh, 
2014). A randomized clinical study (NCT01375699) analyzed the effect of adjuvant treatment 
with the phosphodiesterase 5 inhibitor sildenafil and found no cardioprotection (Poklepovic et 
al., 2018). A recent meta-study suggested that the preventive use of β-blockers lowers the 
risk of ACT by mitigating the reduction in LVEF and possibly preserving the diastolic function 
(Shah et al., 2019). Barbosa and colleagues concluded in their meta-study that not all beta-
blockers are suitable to avert ACT. While carvedilol and nebivolol showed a positive effect in 
clinical trials, the use of metoprolol showed no clear benefits (Barbosa et al., 2018). The 
authors did not specify which properties of the β-blockers were beneficial for ACT prevention. 
In addition, studies have found a number of antioxidants that could limit the ROS-induced 
side effects of DOX treatment (reviewed by Lindsey et al., 2014).  Dexrazoxane has emerged 
as cardioprotective adjuvant for DOX treatment and has already been established in the 
clinic (Hasinoff et al., 2003; McMurray et al., 2014; Yancy et al., 2017). As an iron chelator, it 
has a completely different mode of action than conventional cardioprotective drugs 
(Kaiserová et al., 2007). Its cardioprotective properties are thought to stem from antioxidant 
properties that prevent the formation of highly reactive hydroxyl radicals (Hasinoff et al., 
2003). A careful risk assessment based on the genetic background of the cancer patient, 
combined with new delivery paths and adjuvant cardioprotective treatment, will further limit 
the occurrence of ACT. 
2.1.6. Current treatment and emerging therapies 
Current treatment of ACT does not differ much from standard heart failure treatment. A more 
specific treatment regimen will be necessary to reduce the mortality rate and improve the 
standard of living of ACT patients. The guidelines published by the American College of 
Cardiology and the American Heart Association as well as the European Society of 
Cardiology already support the use of dexrazoxane as an adjuvant drug for ACT treatment 
resulting from DOX exposure (McMurray et al., 2012; Yancy et al., 2013, 2017). Furthermore, 
there is no ACT-specific treatment recommendation (Volkova and Russell, 2011; Zamorano 
et al., 2017). In a 2016 European Society of Cardiology position paper, the group 
recommended considering the lower limit of normal LVEF in echocardiography as 50% 
compared to LVEF before DOX treatment (Zamorano et al., 2017). If LVEF decreases to less 
than 50%, the authors recommended ACE inhibitors (or ARBs), in combination with beta-
blockers to prevent further LV dysfunction and progression to symptomatic CHF (Zamorano 




treatment protocol (Yancy et al., 2013; Cardinale et al., 2015). Furthermore, the authors 
suggested the use of ACE inhibitors (or ARBs) and β-blockers in patients with symptomatic 
CHF or asymptomatic cardiac dysfunction (Zamorano et al., 2017). A retrospective study 
concluded that the use of β-blockers and renin-angiotensin inhibitors leads to LV functional 
recovery in ACT when applied within one year of cancer treatment (Ohtani et al., 2019). For 
late-onset ACT, the antihypertensive drug sacubitril (neprilysin inhibitor), combined with the 
angiotensin receptor blocker valsartan, proved to be effective (Sheppard and Anwar, 2019). 
Randomized, prospective trials need to follow these findings to confirm the benefit for cancer 
patients. 
Despite increasing awareness of ACT among oncologists as well as improved monitoring 
and treatment of cancer survivors, mortality due to cardiac conditions is an increasingly 
important factor of overall prognosis after cancer (McGowan et al., 2017). In a study of 
64,000 female breast cancer patients, cardiovascular diseases were the leading cause of 
mortality surpassing recurrent breast cancer (15.9% vs. 15.1%) after a median nine-year 
follow-up (Patnaik et al., 2011). Female breast cancer patients, who were cancer-free for 
nine years or more, were more likely to die of cardiovascular diseases than of recurrent 
breast cancer. Similarly, in survivors that were treated in their childhood and stayed cancer-
free for 45 years, cardiac deaths accounted for 13% of all deaths (Mertens et al., 2008). 
Thus, with increasing cancer survivorship, cardiovascular mortality has already surpassed 
cancer mortality (McGowan et al., 2017) and is expected to continue to rise. Therefore, it is 
necessary to explore new treatment options directly aimed at ACT-specific disease 
mechanisms. 
2.1.7. Telomerase activation as ACT-specific treatment 
One of many treatment options for ACT-specific disease mechanisms is the activation of 
telomerase enzyme complex. The telomerase enzyme complex adds tandem TTG GGG 
repeats to existing terminal repeat sequences at the 3’ end of DNA strands (Greider and 
Blackburn, 1985). Telomerase activity usually decreases with age, but reportedly increases 
in response to injury (Poss et al., 2002). Although telomerase expression is low in 
mammalian hearts, it exerts a pivotal function. In injured mouse hearts, telomerase 
expression increases not only in endothelial cells and fibroblasts but also in cardiomyocytes 
(Richardson et al., 2012). Telomerase reverse transcriptase (TERT) is the catalytic subunit of 
the telomerase enzyme comlex and the rate-limiting component for telomerase activity 
(Harrington et al., 1997; Kilian et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997; 
Bodnar et al., 1998). The introduction of TERT into cultured cells made the cells overcome in 
vitro cellular senescence, which used to be inevitable as soon as they reached the Hayflick 
limit (Hayflick and Moorhead, 1961; Hayflick, 1965; Bodnar et al., 1998). Today, it is known 




and apoptosis. Hence, telomere maintenance was named a key component for unlimited 
replication in cancer cells (Hanahan and Weinberg, 2000). 
Most telomere research in the past decades has been carried out in the context of cancer 
and aging. However, more recently, the importance of telomere length and telomerase 
activity in cardiovascular diseases has become evident (Figure 2-1) (Yeh and Wang, 2016). 
Short telomeres have been identified as cornerstones of heritable cardiomyopathies 
(reviewed by Chang and Blau, 2018), and telomerase activation has been proposed for 
telomere-associated diseases and telomeropathies in the context of cardiovascular disease 
(Martínez and Blasco, 2018). Bär and Thum speculated that cancer patients would benefit 
from telomerase activation regarding cardiotoxicity with few disadvantages to anti-cancer 
treatment (Bär and Thum, 2017). High telomerase activity has been linked to low 
mitochondrial H2O2 production and cardioprotection in mice after myocardial infarction (MI) 
(Bär et al., 2014; Beyer et al., 2016; reviewed by Quryshi et al., 2018). Under oxidative 
stress, TERT is excluded from the nucleus and is relocated to mitochondria (Haendeler et al., 
2004, 2009). There it decreases the production of mitochondrial ROS and, hence, limits the 
occurrence of more oxidative stress (Beyer et al., 2016). DOX treatment increases cellular 
ROS levels so that telomerase activation decreased the burden on cardiac cells. Telomerase 
activation also restored telomeres that were shortened by oxidative stress (von Zglinicki, 
2002, 2006), and therefore increased cellular lifespan. The heart displays regenerative 
potential, however, the potential of CMs is limited (Rosenzweig, 2012). Elongation of 
telomeres and TERT activation is likely to extend cellular lifespan in CMs and would possibly 






Telomere	 length	 is	 influenced	 by	 genetic	 and	 non-genetic	 factors.	 Once	 telomeres	 reach	 critically	
short	 lengths	 senescence	 is	 triggered	 and	 limits	 cellular	 function.	On	 a	 larger	 scale,	 senescence	 of	
cardiac	 cells	 contributes	 to	 cardiovascular	 disease.	 From	 Yeh	 and	 Wang,	 2016,	 shared	 under	 the	
creative	commons	attribution	license.	
2.2. Disease modeling with induced pluripotent stem cells 
Pluripotent stem cells are defined by their ability to self-renew and to differentiate into cells of 
all three germ layers and the germline (Jaenisch and Young, 2008). In the past, most stem 
cell research was carried out with embryonic stem cells (ESCs), which entailed ethical 
concerns (King and Perrin, 2014; Ilic and Ogilvie, 2017). In 2006, Takahashi and Yamanaka 
reported the reprogramming of murine fibroblasts into cells with properties of pluripotent stem 
cells (Takahashi and Yamanaka, 2006). Retroviral transduction of four transcription factors 
(octamer-binding transcription factor [Oct]-3/4, sex determining region Y-box 2 [SOX2], C-
MYC, and Krüppel-like factor 4 [KLF4]) was sufficient to yield pluripotent stem cells, which 
resembled ESCs in many criteria including self-renewal, morphology, expression of 
characteristic pluripotency genes, teratoma formation, and chimera development (Figure 2-2) 
(Takahashi and Yamanaka, 2006). Subsequently, it was shown that reprogramming of 
fibroblasts could also be done successfully with a different combination of transduced 




(Takahashi et al., 2007). For this groundbreaking work, Yamanaka was awarded the Nobel 
prize in Physiology or Medicine in 2012, which underlines the importance of this discovery. 
Soon after the initial reports, reprogramming had been done in a large set of cell types (Park 
et al., 2008). For differentiation into CMs with a high yield, Burridge and colleagues proposed 
a straightforward three-step protocol (Burridge et al., 2014), which modulated the canonical 
Wnt pathway. Effective modulation of this pathway through small molecules had been 
reported earlier (Gonzalez et al., 2011; Ren et al., 2011; Lian et al., 2013). In the proposed 
differentiation protocol, the Wnt pathway is activated through inhibition of glycogen synthase 
kinase 3 (GSK3), which steers induced pluripotent stem cells (iPSCs) into mesodermal 
differentiation. Subsequent inactivation of the pathway through inhibitor of Wnt production 2 
(IWP2) guides the differentiation towards iPSC-derived CMs (iPSC-CMs). To be able to 
detect differences in cardiomyocyte-specific parameters, it is important to have a high purity 
in the produced iPSC-CMs. High purity can be achieved with metabolic selection, in which 
their ability to metabolize lactate is used to purify iPSC-CMs. Selection media is glucose 
depleted and supplemented with lactate, which offers sufficient energy for iPSC-CMs, but not 
for other cell types (Tohyama et al., 2013). 
iPSC-CMs offer the possibility to model human cardiac diseases and study them in a defined 
in vitro system. Over the past years, several disease models have been established. For 
example, Maillet and colleagues showed that disruption of TOP2B, which is associated with 
ACT in mouse studies, significantly reduced the perceptibility of human iPSC-CMs to DOX-
induced DNA double-strand breaks and cell death (Maillet et al., 2016). Our group and others 
have successfully modeled DOX-induced cardiotoxicity (Burridge et al., 2016; Haupt, 2018) 
and showed that iPSC-CMs from patients recapitulate the predilection towards ACT. More 
recently, the development of a different form of anti-cancer-therapy-induced cardiotoxicity 
was successfully modeled with patient-specific iPSC-CMs: trastuzumab-induced 
cardiotoxicity. The authors reported that iPSC-CMs from affected individuals were more 
susceptible to trastuzumab treatment compared to iPSC-CMs from healthy controls (Kitani et 
al., 2019). In contrast to iPSC-CMs treated with DOX, trastuzumab-treated iPSC-CMs did not 
show cell death or sarcomeric disorganization. However, contractile function and calcium-
handling of iPSC-CMs were impaired, which was partially attributed to decreased 
mitochondrial activity and aberrant cellular metabolic pathways (Kitani et al., 2019). 
2.2.1. iPSC lines from cancer patients with and without ACT 
In our group, an ACT study cohort of three ACT-iPSC lines and two matching control iPSC 
lines were generated and characterized (Haupt, 2018). Patient selection and generation of 
the iPSC lines have been described in detail (Haupt, 2018). Briefly, patients were selected 
from the RICOVER 60 trial (Pfreundschuh et al., 2008) according to the occurrence of ACT 




(Figure 2-2). At the time of the sample collection, three patients had developed ACT, while 
the control patients had no cardiac disease (Figure 2-2). 
Furthermore, the three ACT patients showed homozygous or heterozygous SNPs in the 
RAC2 gene that encodes for an activator of the NADPH oxidase. These SNPs have been 
associated with ACT development in clinical studies (Wojnowski et al., 2005; Reichwagen et 
al., 2015; Vulsteke et al., 2015; Leong et al., 2017). The two control patients did not show the 
respective SNPs. From each patient, two cell lines were characterized and differentiated into 
iPSC-CMs. Haupt showed that after DOX treatment, iPSC-CMs from ACT patients differed 
from control iPSC-CMs in calcium handling, sarcomeric regularity, ROS production, and 
apoptosis rates (Haupt, 2018). Overall, ACT was successfully modeled in vitro by showing 









Cancer	patients	were	 treated	with	Doxorubicin.	One	part	of	 them	developed	ACT	over	 time,	while	
the	 other	 part	 did	 not	 suffer	 from	 cardiac	 disease.	 Skin	 fibroblasts	 from	ACT	 patients	 and	 control	
patients	were	 reprogrammed	 into	 iPCs	 (induced	 pluripotent	 stem	 cells)	 using	 viral	 transduction	 of	
the	Yamanka	 factors	KLF4,	C-MYC,	SOX2,	 and	OCT4.	 iPSCs	were	differentiated	 into	 iPSC-CMs	 (iPSC-
derived	 cardiomyocytes).	 The	 ACT	 patient	 specific-	 and	 control	 patient-specific	 iPSC-CMs	 were	
studied	with	different	biological	assays.		
2.2.2. CRISPR & iPSCs 
The discovery of the clustered regularly interspaced short palindromic repeats (CRISPR) 
locus (Mojica et al., 1993) together with the identification of the CRISPR-associated 9 (Cas9) 
enzyme and the protospacer adjacent motif (PAM; Bolotin et al., 2005) paved the way for the 
development of a novel, simple, fast, and specific tool for genome editing. In 2012, two 
independent groups presented a CRISPR/Cas9 system, in which CRISPR RNA (crRNA) and 
trans-activating RNA are fused to one guide RNA (gRNA), which can theoretically be 
designed to target any DNA site by simply changing the sequence of the crRNA (Gasiunas et 
al., 2012; Jinek et al., 2012). Soon after that, the system was successfully adapted to 
eukaryotic cells (Cong et al., 2013). This adaption enabled researchers to develop in 
vivo repair approaches for genetic diseases and has, therefore, been praised as “resolving 
the taxonomy of human disease” (Merkle and Eggan, 2013). CRISPR/Cas9 also potentiated 
disease modeling with iPSCs (Hockemeyer and Jaenisch, 2016). A former obstacle of iPSC 
disease modeling was the creation of meaningful controls. With CRISPR/Cas9, it is possible 
to alter single or multiple risk alleles specifically. In this way, disease-associated mutations 
can be introduced in iPSCs from healthy individuals, or mutations in patient-iPSCs can be 
corrected (Figure 2-3). These isogenic controls, which only differ in the respective risk allele, 
allow for relevant comparisons and valid conclusions. In the field of cardiovascular research, 
many diseases with genetic causes have successfully been modeled with CRISPR/Cas9-
edited iPSCs (reviewed by Motta et al., 2017). The combination of CRISPR/Cas9 editing and 
iPSCs was pronounced as “a platform for personalized and precision cardiovascular 
medicine” (Matsa et al., 2016). For ACT modeling, the tool can facilitate the identification of 
genetic causes and risk factors. Most recently, CRISPR/Cas9-edited iPSC models were 
reported for Noonan syndrome (Higgins et al., 2019; Jaffré et al., 2019), effective truncations 
in titin and dystrophin (Pioner et al., 2019; Zaunbrecher et al., 2019), functional annotation of 
cTnT (cardiac muscle troponin T) (Lv et al., 2018), and short- and long QT syndrome (Guo et 








2.3. Dilated cardiomyopathy (DCM) 
Dilated cardiomyopathy (DCM) is caused by a dilation of the left ventricular wall, which 
impairs the heart’s ability to pump blood effectively (Dec and Fuster, 1994; Cabrera Cabrera, 
1999). Hence, DCM is often accompanied by a reduction of LVEF and leads to heart failure 
symptoms like fatigue or shortness of breath. In most cases, the initial factor for the onset of 
the condition remains unknown, therefore, DCM is also known as ‘idiopathic’ cardiomyopathy 
(Elliott, 2000). DCM can have genetic causes, most commonly affecting the large sarcomeric 
protein titin (Kamisago et al., 2000; Gerull et al., 2002; Hinson et al., 2015). DCM can also be 
triggered by a variety of other factors, including previous cardiovascular disease (Khasnis et 
al., 2005), alcoholism, diabetes, thyroid disease, viral infections of the heart, heart valve 
abnormalities, childbirth (Patten et al., 2012), or drugs (such as doxorubicin) that trigger 
cardiotoxicity (reviewed by Japp et al., 2016). The diagnosis of DCM occurs after other 
cardiomyopathies such as hypertensive heart disease, myocardial non-compaction, and 
athlete’s heart are excluded (reviewed by Japp et al., 2016). Especially in the case of 
anthracycline-induced DCM, it would be beneficial to detect disease onset before clinical 
sympthoms arise. That would offer the opportunity to adjust or abrogate anthracycline 
treatment and avoid further adverse effects on the heart. While electrocardiogram and 




al., 2005; Fatkin et al., 2011), myocardial strain imaging by echocardiography has proven to 
be a reliable method to detect early signs of ACT (reviewed by Thavendiranathan et al., 
2014). In that case, a reduction of more than 10% in longitudinal strain is a clear indicator of 
developing ACT (reviewed by Japp et al., 2016). It is still unknown whether genetics, 
anthracyclines, or other causes drive disease onset in distinctly different ways, or whether 
there are common molecular processes that lead to a DCM phenotype. Our group and others 
have modeled inherited DCM with patient-specific iPSC-CMs (Sun et al., 2012; Streckfuss-
Bömeke et al., 2017). Together with iPSC lines from ACT patients, this approach has the 
potential to unravel differences and similarities in basic cardiomyopathy mechanisms.  
2.4. Aim of the study 
DOX treatment has multiple and profound effects on CM homeostasis. The aims of this study 
are: 
• Analyze the resorption and intracellular distribution of DOX in iPSC-CMs from ACT 
patients and control patients. 
• Identify the molecular effects of DOX on basic processes including mRNA translation in 
iPSC-CMs from ACT and control patients. 
• Edit the ACT-associated SNP rs13058338 in NADPH-oxidase subunit RAC2 into wild-
type with CRISPR/Cas9 gene editing. 
• Explore the potential of adeno-associated virus 6 (AAV6)-mediated overexpression of 
TERT as ACT-specific treatment. 





This section lists patient materials, consumables, chemicals, commercial kits, and assays, 
antibodies, buffers, solutions, and media that were used for this study. 
3.1. Patient materials for iPSC lines 
iPSC lines created from cardiomyopathy patients, cancer patients, and healthy controls were 
used in this study. Relevant background information about the donors, their disease status, 
and the type of somatic material are listed below. 
§ ACT patient 1: Derived from skin fibroblasts (sFB) of a 69-year old male B-cell 
lymphoma patient with ACT (309 mg/m2 median DOX treatment).  
§ ACT patient 2: Derived from sFB of a 71-year old male B-cell lymphoma patient with 
ACT (309 mg/m2 median DOX treatment).  
§ ACT patient 3: Derived from sFB of a 66-year old female B-cell lymphoma patient 
with ACT (309 mg/m2 median DOX treatment).  
§ Control patient 1: Derived from sFB of a 66-year old male B-cell lymphoma patient 
without cardiac complaints following anthracycline chemotherapy (318 mg/m2 median 
DOX treatment).  
§ Control patient 2: Derived from sFB of a 68-year old male B-cell lymphoma patient 
without cardiac complaints following anthracycline chemotherapy (318 mg/m2 median 
DOX treatment).  
§ DCM 1: Derived from sFB of a 44-year-old male patient with a sudden dilative 
cardiomyopathy from the Department of Cardiology and Pneumology, University 
Medical Center Göttingen. 
§ DCM 3: Derived from peripheral blood mononuclear cells (PBMCs). 
§ Ctr-DCM 2: Derived from PBMCs of a non-consanguineous family member of DCM 1 
with no recorded history of cardiovascular disease from the Department of Cardiology 
and Pneumology, University Medical Center Göttingen. 
§ CRT1: Derived from PBMCs of a healthy, 52-year-old female individual with no 
recorded history of cardiovascular disease. Department of Cardiology and 
Pneumology, University Medical Center Göttingen. 
All procedures were conducted in compliance with the Institutional Ethical Committee, 
University Medical Center Göttingen. Written informed consent was received from the 
participants before inclusion. The study conforms to the World Medical Association 
declaration of Helsinki. An overview of the iPSC lines and their respective method of 













ACT patient 1.1 ACT 1.9 Sendai skin fibroblasts Haupt, 2018 
ACT patient 1.2 ACT 1.10 Sendai skin fibroblasts Haupt, 2018 
ACT patient 2.1 ACT 2.9 Sendai skin fibroblasts Haupt, 2018 
ACT patient 2.2 ACT 2.14 Sendai skin fibroblasts Haupt, 2018 
ACT patient 3.1 ACT 3.1 Sendai skin fibroblasts Haupt, 2018 
ACT patient 3.2 ACT 3.11 Sendai skin fibroblasts Haupt, 2018 
Control patient 1.1 ACT K1.2 Sendai skin fibroblasts Haupt, 2018 
Control patient 1.2 ACT K1.8 Sendai skin fibroblasts Haupt, 2018 
Control patient 2.1 ACT K2.2 Sendai skin fibroblasts Haupt, 2018 
Control patient 2.2 ACT K2.9 Sendai skin fibroblasts Haupt, 2018 
DCM 1.6 sDCM 1.6 Sendai skin fibroblasts Unpublished 
DCM 1.10 sDCM 1.10 Sendai skin fibroblasts Unpublished 
Crt-DCM 2.1 sDCM 2F1 Sendai PBMCs Unpublished 
Crt-DCM 2.2 sDCM 2F2 Sendai PBMCs Unpublished 
DCM 3.7 sDCM 3.7 Sendai PBMCs Unpublished 
CRT1 pCTRL1.1 Plasmid PBMCs Borchert et al., 
2017 
Phoenix Phoenix Sendai cord blood 
cells 
Haase et al., 
2017 
PBMCs: Peripheral blood mononuclear cells 
 
3.2. Laboratory materials 
3.2.1. Chemicals, kits, and media 
Chemicals, commercial kits, and basic cell culture ingredients are listed in Table 3-2 with 
their respective supplier.  
Table	3-2:	Chemicals,	kits,	and	media	
Item Supplier 
100 bp+ DNA ladder Thermo Fisher # 15628019 
10-cm dish, TC-treated  CytoOne Starlab # CC7682-3394 
12-well plate, TC-treated  CytoOne Starlab # CC7682-7512 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) 
Sigma # H3375 
4.6-diamino-2-phenylindole, 0.2 ng/ml (DAPI) Sigma-Aldrich # D9542 
6-cm dish, TC-treated  CytoOne Starlab # CC7682-3359 
6-well plate, TC- treated  CytoOne Starlab # CC7682-7506 
Acetonitrile, 100% HPLC-grade  Fisher Scientific # A996-1 
Alt-R Cas9 electroporation enhancer IDT # 1075915 
Alt-R CRISPR-Cas9 tracrRNA IDT # 1072532 




Amaxa nucleofector system, human stem cell 
nucleofectorTM kit 1 
Lonza # VPH-5012 
Amersham protran premium 0.45 µm 
nitrocellulose blotting membrane 
GE Healthcare, Life science 
# 10600003 
Amplex Red Hydrogen Peroxide/Peroxidase 
Assay Kit (Amplex red kit) 
Thermo Fisher Scientific # A22188 
APC-Annexin V apoptosis detection kit with 
PI 
BioLegend # 640932 
B-27 supplement, 50x, serum free Thermo Fisher Scientific # 17504044 
 
Black 96-well microplate Berthold Technologies # 23302 
Boric acid  Sigma-Aldrich # 15663 
Bovine albumin fraction V solution (bovine 
serum albumin, BSA, 7.5%)  
Thermo Fisher Scientific #15260037 
Bradford reagent Sigma-Aldrich # B6916 
Bromophenol blue Sigma # B0126 
Cell scraper: 2-Posit. Blade 25  Sarstedt # 83.1830 
CHIR99021 (CHIR) Merck Millipore # 361559 
CryoTube vials Thermo Fisher Scientific # 377224 
Diethylenetriaminepentaacetic acid (DTPA) Sigma-Adlrich # D6518 
Dimethyl sulfoxide (DMSO)  Sigma-Aldrich # D2650 
Dithiothreitol (DTT) Sigma # GE17-1318-01 
DMEM-F12 Thermo Fisher Scientific # 31331028 
Doxorubicin hydrochloride  Sigma-Aldrich # D1515 
Dulbecco's modified Eagle medium (DMEM) Thermo Fisher Scientific #11960044 
Dulbecco's phosphate-buffered saline (PBS) Thermo Fisher Scientific #14190144 
Essential 8 medium and supplement 
(E8 medium)  
Thermo Fisher Scientific # A1517001 
Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA) 
Sigma-Aldrich # E3889 
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich # E6758 
Falcon round-bottom polystyrene tubes, 5 ml Stem cell technologies # 38007 
Fetal bovine serum (FBS) Sigma-Aldrich # F7524 
Filter tips: 0.1–1000 µl Starlab #S1120-3810, # S1122-1830, 
#S1120-1840 
Fujifilm super RX-N medical X-ray film Fujifilm # 47410 19289 
Gelatin  Sigma-Aldrich # 48720 
Geltrex Thermo Fisher Scientific # A1413302 
Glass cover slips, round 25 mm R. Langenbrinck # 01-0025/2 
Glycine Sigma # G8898 
Gradient gel, Bolt 4%-12% Bis-Tris Plus Thermo Fisher Scientific 
# NW04125BOX 




IDTE (1x TE buffer: 10 mM Tris, 0.1 mM 
EDTA) 
IDT # 11-05-01-05 
Inhibitor of Wnt production 2 (IWP2) Merck Millipore # 681671 
Iscove's modified Dulbecco's medium 
(IMDM) with GlutaMAX 
Thermo Fisher Scientific # 31980030 
L-Ascorbic acid 2-phosphate Sigma Aldrich # A8960 
L-glutamine (200 mM)  Thermo Fisher Scientific # 25030024 
Luminol Sigma # A8511 
Methanol  Merck Millipore # 106009 
MG-132 Sigma-Aldrich # 474790 
Microcentrifuge polypropylene tube 
(ultracentrifuge tube) 
Beckman Coulter # 357448 
Midori Green Advance  Biozym # 617004 
Monothioglycerol (MTG) Sigma-Aldrich # M1753 
Mr. Frosty freezing container Thermo Scientific # 5100-0001 
Non-essential amino acids (NEAA)  Thermo Fisher Scientific # 11140035 
Non-fat dry milk  Roth # T145 
Nuclease-free water  Thermo Fisher Scientific # AM9932 
Nucleofector 2b Device Lonza # AAB-1001 
Object slides (76 x 26 mm) Thermo Fisher Scientific 
# 10143562C 
Oligo d(T)16 (50 µM)  Thermo Fisher Scientific # N808-
0128 
P-Coumaric acid Sigma # C9008 
Pasteur pipettes, glass TH Geyer # 7691061 
Penicillin/streptomycin Thermo Scientific # 15140-122 
PeqGold universal agarose  Peqlab # 35-1020 
Phenylmethanesulfonyl fluoride (PMSF) Sigma # P7626 
Pierce bovine serum albumin standard 
ampules, 2 mg/ml, (protein standard) 
Thermo Scientific # 23209 
Polypropylene screw neck cap and preslit 
PTFE/silicone septum (HPLC tube) 
Waters # 186000305 
Ponceau S solution Sigma-Aldrich # P7170-1L 
Protease inhibitor cocktail Millipore # 535140 
Puromycin dihydrochloride (puromycin) Sigma # P9620 
QIAamp DNA mini kit (50) Qiagen # 51304 
QIAquick gel extraction kit  Qiagen # 28706 
QuantiNova reverse transcription kit Qiagen # 205413 
Recombinant human basic fibroblast growth 
factor (hbFGF) 
PeproTech # 100-18B 
ReliaPrep RNA tissue miniprep system Promega # Z6110 




Medium (RPMI medium) with HEPES and 
GlutaMAX 
 
Roswell Park Memorial Institute 1640 
Medium (RPMI medium), no glucose 
Thermo Fisher Scientific # 11879020 
Roti-Histofix 4% (Histofix) Carl Roth # P087.5 
Sodium chloride (NaCl) Sigma # S7653 
Sodium DL-lactate solution 60% (w/w) Sigma-Aldrich # 2326 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich # L4509 
Sodium fluoride (NaF)   Roth # P756 
Sodium orthovanadate Sigma-Aldrich # S6508 
StemFlex basal medium (StemFlex medium) Thermo Fisher Scientific # A33493-
01 
Steriflip-GP (0.22 µm) Merck Millipore # SCGP00525 
Stripettes: 5 ml, 10 ml, 25 ml, 50 ml Sarstedt # 86.1253.001, 
# 86.1254.001, # 86.1685.001. 
# 86.1256.001 
Sucrose Sigma-Aldrich # S8501 
Superfrost plus adhesion microscope slides  Thermo Scientific # J1800AMNZ 
SV total RNA isolation system  Promega # Z3105 
Tetrasodium pyrophosphate (Na4P2O7) Merck # P8010 
Thiazovivin (TZV) Millipore # 420220 
Trifluoroacetic acid (TFA) Sigma-Aldrich # 302031 
Triton X-100 Sigma # X100 
Trizma base (Tris) Sigma # T1503 
Trypsin-EDTA (0.25%) Thermo Fisher Scientific # 25200056 
Tween 20 Sigma-Aldrich # P2287 
Vectashield mounting medium Linaris Biologische Produkte # H-
1700-2 
Versene Thermo Fisher Scientific # 15040066 
Whatman paper Sigma-Aldrich # WHA3030672 
White filter cards Thermo Scientific # 5991022 
β-Glycerophosphate Sigma # 35675 
β-Mercaptoethanol (β-ME) Serva Electrophoresis # 28625 
	
Millipore water 






3.2.2. Antibodies for protein detection 
Specific antibodies for protein detection using Western blotting were purchased from the 
suppliers listed in Table 3-3 and diluted as described below. 
Table	3-3:	List	of	antibodies	for	Western	blotting	
Antibody Supplier 
Anti-GAPDH antibody, monoclonal, mouse, IgM Sigma-Aldrich # G8795 
Anti-puromycin antibody, monoclonal, mouse, IgG1 kappa  Kerafast, # EQ0001 
Anti-β-actin antibody, monoclonal, mouse, IgG Sigma # A1978 
Anti-β-tubulin antibody, monoclonal, mouse, IgG1 Sigma-Aldrich # T8328 
Goat anti-mouse-HRP Millipore # 401215 
IRDye 800CW donkey anti-mouse IgG secondary 
antibody 
LI-COR # 926-32212 
	
GAPDH antibody solution 
Anti-GAPDH antibody was diluted 1:10,000 in Tris-buffered saline (TBS)-T, 1% milk. 
Puromycin antibody solution 
Anti-puromycin antibody was diluted 1:1,000 in 5 ml TBS-T. 
β-actin antibody solution 
Anti-β-actin antibody was diluted 1:10,000 in 5 ml TBS-T, 1% milk. 
β-tubulin antibody solution 
Anti-β-tubulin antibody was diluted 1:10,000 in 5 ml TBS-T, 1% milk. 
Goat anti-mouse secondary antibody solution 
Goat anti-mouse antibody was diluted 1:10,000 in 5 ml TBS-T, 1% milk. 
Donkey anti-mouse secondary antibody solution 





Antibodies for protein detection by immunocytochemistry and their respective dilution ratio 
are given in Table 3-4. 
Table	3-4:	List	of	antibodies	for	immunofluorescence	staining.	
Antibody Dilution Supplier 
Anti-LIN28, goat, IgG 1:300 R&D systems # AF3757 
Anti-NANOG goat, IgG 1:200 Abcam # PA5-18406 
Anti-OCT4 goat, IgG 1:40 R&D systems # AF1759 
Anti-SOX2 mouse, IgG 1:50 R&D systems # MAB2018 
Anti-SSEA4 mouse, IgG 1:200 Abcam # MC813 
Anti-TRA-1-60 mouse, IgM 1:200 R&D systems MAB4770 
Anti-α-actinin mouse, IgG 1:1000 Sigma-Aldrich # A7811 
Anti-titin M-Line 1:1000 Abcam # ab193218 
Goat anti mouse IgM, FITC 1:200 Jackson ImmunoResearch 
Laboratories # 115-095-020 
Donkey anti goat IgG, Alexa Fluor 555 1:1000 Thermo Fisher Scientific # A21432 
Donkey anti mouse IgG, Alexa Fluor 488 1:1000 Thermo Fisher Scientific # A21202 
 
Antibody solutions for immunofluorescence (IF) staining  
All antibodies for IF staining were diluted in TBS, 1% milk with the dilution factor specified in 
Table 3-4. 
3.3. Cell culture media and buffers 
Media, solutions, and buffers were prepared freshly as described below and stored at +4°C 
for short term or at -20°C for long term. 
Amplex red working solution 1 
1.6 µL of 10 mM Amplex red reagent stock solution + 3.2 µL 10 U/mL HRP stock solution in 
315.2 µL 1x reaction buffer. 
Amplex red working solution 2 
6.5 µL 10 mM Amplex red reagent stock solution + 13 µL 10 U/mL HRP stock solution in 
630.5 µL 1x reaction buffer. 
Blocking buffer 
5% milk: 1 g milk powder in 20 ml TBS-T. 
Cardio culture medium 




Cell lysis buffer 
10 mM HEPES, 50 mM NaCl, 0.5 M sucrose, 0.1 mM EDTA, 0.1 mM EGTA, 0.5% 
Triton x 100, 1 mM DTT, 10 mM Na4P2O7, 100 mM NaF, 17.5 mM β-glycerophosphate, 1 mM 
PMSF, 10 mM sodium orthovanadate, 5 µl/ml protease inhibitors, and 1 µl/ml MG-132 in 
Millipore water. 
Differentiation medium 
RPMI medium with HEPES and GlutaMAX supplemented with 0.02% L-Ascorbic acid 2-
phosphate and 0.05% BSA. 
Enhanced chemiluminescence (ECL) 
100 µl luminol (0.44 g in 10 ml DMSO) and 44 µl p-coumaric acid (0.15 g in 10 ml DMSO) in 
20 ml 100 mM Tris. Mix well, add 17 µl H2O2 concentrate (10 mM). Mix well, protect flask 
from light and store at 4°C. Re-use up to 5 times within one week. 
Freezing medium 
Stem Flex, 10% DMSO, 2 µM TZV. 
HbFGF 
100 mg dissolved in 1 ml of 5 mM Tris and stored at -20 °C. For use in cell culture the stock 
was diluted 1:10 with 0.1% BSA for a working concentration of 10 ng/µl and stored at 4 °C.  
Iscove medium 
IMDM with GlutaMAX supplemented with 20% heat-inactivated FBS, 1x NEAA and 450 µM 
MTG. 
Running buffer 
25 mM Tris, 192 mM glycine, 0.1% SDS in Millipore water 
Sample buffer (4x) 
40% Glycerol, 40% SDS, and 1 mM bromophenol blue in 250 mM Tris at pH 6.8 with 
100 mM HCl 
Selection medium 
RPMI medium without glucose, supplemented with 0.02% L-Ascorbic acid 2-phosphate, 
0.05% BSA, and 4 mM lactate 
TBS 
10 mM Tris, 150 mM NaCl in Millipore water, pH 7.4 
TBS-T 





25 mM Tris, 192 mM glycine, 10% methanol in Millipore water  
Tris-borat-EDTA (TBE)-buffer 






4.1. iPSC culture and passaging 
4.1.1. iPSC culture 
iPSCs were cultured with E8 medium with daily media changes on Geltrex-coated dishes in a 
humidified incubator at 37°C and 5% CO2 (standard conditions). To coat the dishes, 2 mg 
frozen Geltrex was dissolved in 12 ml ice cold DMEM-F1. The dishes were covered with the 
Geltrex solution and incubated at 37°C for 30-60 minutes (min) or at 4°C overnight.  
4.1.2. iPSC passaging with Versene on Geltrex 
iPSCs were passaged twice a week to avoid spontaneous differentiation favored by high cell 
density. Geltrex-coated plates, E8 medium, and Versene were warmed to room temperature 
(RT). Old media was aspirated, iPSCs were washed twice with Versene solution and 
carefully incubated with Versene for 3-5 min with minimal movement at RT. When iPSCs 
began to detach, Versene was aspirated and the cells were detached from the plate with E8 
medium supplemented with 2 µM TZV. The desired number of iPSCs was transferred onto 
the Geltrex-coated plates and cultured with E8 and 2 µM ROCK inhibitor TZV under standard 
conditions over night. The following day the medium was replaced to E8 media without TZV. 
iPSCs from DCM 1, ctrl-DCM 2, and gene-corrected ACT-iPSCs were cultured in StemFlex 
medium. StemFlex medium was changed every other day. 
4.2. Spontaneous differentiation 
Spontaneous differentiation into different germ layers showed the pluripotent capacity of 
iPSCs. Our media did not contain factors that direct the differentiation into a specific cell-
type. To generate embryoid bodies (EBs), iPSCs of about 80% confluency were grown on 
mouse embryonic fibroblasts (MEFs) feeder layer and then transferred to a non-coated 6 cm 
suspension culture dish in DMEM-F12 with GlutaMAX and 20% Knock-Out Serum 
Replacement, 1% NEAA, 1% β-ME, 10 ng/ml hbFGF. Cells were incubated at 37°C 
overnight. When EBs had formed, they were carefully washed with Iscove medium, 
transferred into a non-coated 6 cm suspension culture dish, and cultivated in Iscove medium 
in suspension at 37°C for eight days. The medium was changed on day four and seven after 
the start of differentiation. On day eight, about 30 EBs were plated on 0.1% gelatin-coated 
culture plates and on 0.1% gelatin-coated culture plates containing glass cover-slips, 
respectively. EBs were cultivated for another 25 days in Iscove medium, which was replaced 
every two days. EBs in the culture plates were used for semiquantitative polymerase chain 
reaction (PCR). 
4.3. Directed differentiation and cardiomyocyte culture 
For each donor, two iPSC lines were directly differentiated in vitro into 95% pure 




Differentiation was initiated by culturing iPSCs in differentiation media plus 4 µM CHIR for 
48 hours (48 h). CHIR inhibits GSK3 and hence activates the canonical Wnt pathway. After 
48 h, the cells were incubated with 5 µM IWP2 in differentiation media for another 48 h to 
inhibit Wnt signalling. After that, cells were cultured for 48 h in plain differentiation media and 
subsequently in cardio culture medium. Cardio culture medium was changed every two days. 
Three to four weeks after the start of the differentiation the cells were metabolically selected 
by culturing them in selection media for 4–5 days. iPSC-CMs were cultured with two media 
changes per week for at least 60 days to receive matured iPSC-CMs. Five to seven days 
before the respective experiment, iPSC-CMs were replated to control cell number and to 
grow them on an appropriate dish. iPSC-CMs were detached from the culture plate with 
0.25% trypsin/EDTA for 5–7 min at 37°C. Detached cells were transferred to a 15 ml tube 
and the trypsin reaction was stopped with FBS. The cell solution was centrifuged for 5 min at 
200 x g. The supernatant was discarded, cells were resuspended in 1 ml FBS, counted in a 
Thoma-counting chamber, and seeded on Geltrex-coated plates with cardio culture medium, 
20% FBS, and 2 µM TZV. After 48 h, the medium was changed to cardio culture. If not 
indicated otherwise, two- to three-month-old iPSC-CMs were exposed to DOX for 24 h with 
concentrations ranging from 0.1 µM DOX to 5 µM DOX. Further treatment, harvest or other 
handling was dependent on the assay and is described with the respective experiment. 
4.4. DOX measurements with HPLC 
4.4.1. Sample preparation for intracellular DOX measurement 
Intracellular DOX levels were analyzed according to an adapted protocol for dihydroethidium 
(DHE) measurement (Fernandes et al., 2007). DOX-challenged iPSC-CMs were washed 
twice with PBS plus 100 µM DTPA (PBS-DTPA) and immediately lysed with 500 µl 
acetonitrile. Cells were detached from the plate with a cell scraper. Detached lysates were 
transferred to 1.5 ml tubes and centrifuged at 10,000 x g for 10 min in a cooled table-top 
centrifuge (Eppendorf 5418 R). The supernatant was transferred to a fresh tube, dried in a 
vacuum concentrator (Speed Vac with vacuum pump and refrigerated vapor trap, Thermo 
Fisher Scientific), resuspended in PBS-DTPA, transferred to a 300 µl HPLC tube, and lined 
up in a Dionex UltiMate 3000 Autosampler (Thermo Scientific) at 4 °C in the dark for HPLC 
measurement (see 4.4.3). 
4.4.2. Subcellular fractionation for DOX detection 
 DOX-treated iPSC-CM lysates were fractionated throught ultracentrifugation to isolate 
particular cellular compartments: 1) mitochondrial and nuclear fraction (mito fraction), 2) 
membrane fraction, 3) cytoplasmic fraction to determine the subcellular distribution of DOX. 
The separate fractions were measured individually with HPLC for DOX content. First, two 
million DOX-treated iPSC-CMs (1 µM DOX for 24 h) were harvested, lysed in 150 µl Tris-HCl 




fractionation was achieved with ultracentrifugation as described before (Laurindo et al., 2002) 
with minor changes. To receive the mito fraction, sonicated lysates were centrifuged at 
18,000 x g for 30 min in a table-top centrifuge (Eppendorf, 5418 R) at 4°C. 140 µl of the 
supernatant of each condition were transferred to a 1.5 ml ultracentrifuge tube, and 
centrifuged at 47,000 revolutions per minute (rpm) for 1 h at 4°C in a Beckman Coulter 
Optima MAX centrifuge with a TLA-55 rotor. The resulting pellet was the membrane fraction. 
The supernatant was transferred to a new 1.5 ml eppendorf tube and marked as 'cytoplasmic 
fraction' (Figure 4-4). 
	
Figure	4-4:	Schematic	overview	of	the	membrane	isolation	workflow. 
The mito fraction pellets and the membrane fraction pellets were resuspended in 100 µl PBS 
and sonicated. Five µl from each fraction were used for a Bradford assay to determine 
protein concentration as reference (see 4.6.1). 100 µl acetonitrile were added to the rest of 
the samples, and the tubes were immediately vortexed for 10 s. Then, the samples were 
centrifuged at 18,000x g for 15 min in a table-top centrifuge (Eppendorf) at 4°C. The 
supernatant was transferred to a new tube and dried in a Speed Vac with vacuum pump and 
a refrigerated vapor trap (Thermo Fisher Scientific). Dried samples were resuspended in 100 
µl PBS and measured with HPLC. 
4.4.3. HPLC measurement and data processing 
The HPLC set-up consisted of the following units: Flow manager, UV unit, pump (all Dionex), 




with a Thermo Scientific nanoViper connection. Injection volume was 25 µl per sample and 
the flow rate was set to 0.400 ml/min with a pressure of approximately 70 bar. Solution A was 
>99% HPLC-grade acetonitrile with 0.1% TFA and solution B was Millipore grade I-filtered 
water with 0.1% TFA. Initial solution A to solution B ratio was 85%:15%, gradually shifting to 
15%:85% over the measurement period of 40 min. DOX peaks were identified by a reference 
injection of diluted DOX and appeared after a retention time of approximately 16 min. For 
each peak the area under the curve was considered. Peak analysis was carried out with 
Chromeleon 7 software. 
4.5. Nucleic acid isolation and PCR 
4.5.1. RNA isolation 
Pellets of iPSCs and embryonic bodies, respectively, were snap frozen and stored at -80°C. 
The RNA was isolated with the SV Total RNA Isolation System according to the 
manufacturer’s protocol. Briefly, the pellets were lysed with 400–600 µl RNA lysis buffer 
supplemented with β-ME (20 µl/ml). Equal volumes of 95% ethanol were added to the lysate 
and the sample was transferred to a spin-basket tube. The samples were washed with RNA 
wash solution and incubated with DNase I mix for 15 min at RT. The reaction was stopped 
with 200 µl of DNase stop solution. The samples were washed twice and the RNA was eluted 
with 100 µl nuclease-free water. RNA concentration was determined with a NanoPhotometer 
N60 (IMPLEN, Munich, Germany) at 260/280 nm and the samples were stored at -80°C. 
4.5.2. DNA isolation with QIAamp DNA Mini Kit 
Genomic DNA was isolated from iPSCs with the QIAamp DNA Mini Kit according to the 
manufacturer's instructions. The genomic DNA was eluted in 100 µl nuclease-free water. The 
genomic DNA yield was measured with a NanoPhotometer N60 (IMPLEN, Munich, 
Germany) at 260/280 nm and the samples were stored at -80°C. 
4.5.3. DNA amplification with PCR 
To synthesize complementary DNA (cDNA) from our isolated RNA, we used the QuantiNova 
Reverse Transcription Kit according to the manufacturer's protocol. In a first step to remove 
residual genomic DNA from the isolated RNA, 100 ng RNA and 1 µl of genomic DNA 
removal Mix (1x) were mixed in nuclease-free water to a total volume of 15 µl. The mix was 
incubated at 45°C for 2 min and placed on ice immediately. For reverse transcription, 
genomic DNA-free RNA (15 µl), 2 µl of the reverse transcription mix (1x), and 0.5 µl of the 
reverse transcription enzyme were mixed in nuclease-free water to a total volume of 20 µl. 
The reverse transcription mix was incubated in a PCR cycler at 25°C for 3 min, at 45°C for 
10 min and eventually at 85°C for 5 min. For extended storage, synthesized cDNA was 




Amplification of genomic DNA and cDNA sequences was done with PCR. The PCR, first 
described in 1986 (Mullis et al., 1986), contained the following three basic reaction steps, 
which are repeated in various cycles: 1) denaturation of introduced DNA, 2) annealing of 
oligonucleotides at the matrix, and 3) amplification of the target DNA sequence. To initiate 
amplification, two single stranded oligonucleotides (primers) were needed that served as a 
start signal for the DNA-polymerase. One of these oligonucleotides is complementary to the 
sequence at the 5’ end of the sequence to be amplified (forward primer; for), one is 
complementary to the 3’ end of the opposite strand (reverse primer; rev). Components of the 
PCR reaction mix (Table 4-1) and details of the reaction steps (Table 4-2) are displayed 
below.  
Table	4-1:	Required	components	and	their		 	 	
volume	for	PCR		 	 	 	 	 Table	4-2:	Reaction	steps	during	PCR	
Components for PCR Volume for 
one reaction 
(25 µl final) 
cDNA 1 µl 
Nuclease-free H2O 15.3 µl 
5x Green GoTaq 
reaction buffer 
5 µl 
10 mM dNTPs 1.6 µl 
Forward primer (10 µM) 1 µl 





Detailed primer sequences and reaction mixes for reverse transcription and PCR are listed in 
Table 4-3. 
Table	4-3:	Primer	sequences	for	PCR	primers.	








AFP For:  
ACTCCAGTAAACC
CTGGTGTTG 
255 60 33 PCR 
 Rev: GAAATCTGCAATG
ACAGCCTCA 
    
ALB For: CCTTTGGCACAAT
GAAGTGGGTAACC 
355 62 43 PCR 
 Rev: CAGCAGTCAGCCA
TTTCACCATAGG 
    
cTNT For: GACAGAGCGGAAA
AGTGGGA 
305 62 26 PCR 
Process  Temperature  Time  
Denaturing  95°C 3 min 
94°C 15 s 
Annealing  Listed in 
Table 4-3 
15 s 
Synthesis  72 °C 30 s 
72°C 10 min 






    
GAPDH For: AGAGGCAGGGAT
GATGTTCT 
258 60 30 PCR 
 Rev: TCTGCTGATGCCC
CCATGTT 
    
HPRT For: CAAAGATGGTCAA
GGTCGC 
81 60 40 PCR 
 Rev: CAAATCCAACAAA
GTCTGGCT 
    
LIN28 For: AGTAAGCTGCACA
TGGAAGG 
410 52 30 PCR 
 Rev: ATTGTGGCTCAAT
TCTGTGC 
    
NANOG For: AGTCCCAAAGGCA
AACAACCCACTTC 




    
OCT4 For: GACAACAATGAAA
ATCTTCAGGAGA 
473 59 36 PCR 
 Rev: TTCTGGCGCTTAC
AGAACCA 
    
RAC2 For: TTGCCCTGAGAAC
CAAGACC 




    
SOX2 For: ATGCACCGCTACG
ACGTGA 
437 60 34 PCR 
 Rev: CTTTTGCACCCCT
CCCATTT 
    
TH For: GCGGTTCATTGGG
CGCAGG 
215 60 34 PCR 
 Rev: CAAACACCTTCAC
AGCTCG 
    
 
4.5.4. Agarose gel electrophoresis 
To determine the presence and size of amplified DNA sequences, PCR products were 
fractioned with gel electrophoresis. The samples and a DNA ladder were pipetted into the 
pockets of an 1.5% TBE-agarose gel with 0.004% Midori green. The gel was run in TBE 
buffer at 120 V for 20 min.  Fluorescence was captured with a Chemidoc XRS+ imager (Bio-
Rad, Feldkirchen, Germany). 
4.6. mRNA translation assay with puromycin and Western blotting 
4.6.1. Cell lysis and sample preparation 
iPSC-CMs were treated with 1 µM DOX in 1.5 ml/well cardio culture medium for 24 h. Untreated 
controls were cultured in 1.5 ml /well cardio culture medium without DOX. 
Before harvesting, 1 µM puromycin (7.5 µl from 200 µM stock in 1.5 ml medium) was added to 




twice with PBS, and harvested with 120 µl cell lysis buffer. Lysates were sonicated and protein 
content was determined with Bradford reagent according to the manufacturer's 
recommendation. Briefly, 5 µl of protein samples or a protein standard dilution series were 
pipetted in triplicates onto a 96-well plate. 250 µl of the Bradford reagent were added per well 
and the samples were incubated for 10 min at RT. Afterwards, the absorption was detected 
photospectroscopically with a plate reader (Tecan, Männedorf, Switzerland) at 595 nm. The 
absorption values of the protein standard series were used to calculate a standard curve. The 
standard curve was used to calculate sample protein concentrations from the absorption values 
of the samples. 
During the incubation time of the Bradford assay, 40 µl of 4 x sample buffer and 5% β-ME (8 µl 
per sample) were added to the iPSC-CMs protein samples. They were denaturated for 5 min at 
90°C and placed on ice to cool down. 
4.6.2. SDS-gel electrophoresis and Western blot 
Proteins were separated with SDS-polyacrylamide electrophoresis as described before 
(Laemmli, 1970). To this end, equal amounts of protein (15 µg, 8–15 µl of lysate) were loaded 
into the pockets of a precast gradient gel (4–12%). The gel was run for approximately 45 min at 
160 V (PowerPac Basic Power Supply, BioRad) in 1x running buffer. After the run, the gel was 
taken out of the casing and the proteins were transferred to a nitrocellulose membrane with the 
Western blot approach (Towbin et al., 1979). The transfer block contained (from bottom to top) 
sponge, Whatman paper, the polyacrylamide gel, nitrocellulose blotting membrane, Whatman 
paper, and sponge. All parts were briefly washed in transfer buffer before assembly. The 
transfer assembly was placed into a transfer chamber (Bio-Rad) together with an ice-pad and 
transfer buffer. The transfer ran for 80 min at 70 V (PowerPac Basic Power Supply, Bio-Rad). 
After blotting, the membrane was taken out, cut to size and stained with Ponceau Red solution 
to confirm successful transfer.  
4.6.3. Protein detection with specific antibodies 
Ponceau staining was washed out with water and the membrane was blocked in 20 ml blocking 
buffer for 1 h. The membrane was incubated with primary anti-puromycin antibody solution 
over-night on a shaker at 4 °C. The following day, the membrane was washed 3 times for 15 
min with TBS-T and incubated with the secondary antibody for 45 min to 1 h at RT. Afterwards, 
the membrane was washed three times for 15 min with TBS-T. After the last washing step, the 
membrane was incubated with 2–3 ml of ECL solution for 2 min. Then, the ECL solution was 
removed, the membrane was dabbed and luminescence was captured with a medical X-ray 
film. Exposure times varied according to the antibody. Subsequently, the film was developed in 




For loading control, the membrane was rehydrated in Millipore water, blocked in blocking 
solution for 1 h at RT and incubated overnight at 4°C with antibodies directed against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin, or β-tubulin. The following day, 
the membrane was washed three times with PBS for 15 min, incubated with LICOR IRDye 
800CW donkey anti-mouse IgG secondary antibody (1:15,000) in TBS for 40 min at RT, and 
then washed three times with TBS. Fluorescent signals were measured with an Odyssey CLx 
Imaging System (LI-COR). 
Signal quantification was performed with FIJI. Average lane intensities were normalized to 
reference band intensities. 
4.7. Genome editing 
4.7.1. Sequence design and iPSCs preparations 
To edit the SNP in the RAC2 gene, we chose the CRISPR/Cas9 system provided by IDT. 
Guide RNA and homology-directed repair (HDR)-template were designed with IDT and 
mismatch scores were tested with CRISPOR. The final sequence for the guide RNA was 
selected based on the distance of the cutting site to the SNP and the predicted mismatches. 
We chose the guide RNA which had the closest cutting site to the SNP (5 base pairs) and a 
low number of predicted mismatches. Based on the guide RNA, the HDR template was 
designed and both were ordered from IDT. 
iPSCs from our target cell line ACT1.10 were thawed and cultured for at least one week 
before genome editing. The passage of the used iPSC line did not exceed 20. On the day of 
the transfection, the iPSCs had a confluency of 70–80% (1–2 million iPSCs per 6-well). 
Before transfection, cell morphology and density were documented by taking brightfield 
images with an Axio Oberserver light microscope (Carl Zeiss, 4x and 10x magnification).  
 
4.7.2. Complex formation and transfection preparation 
In preparation of the assay, guide RNA, Alt-R CRISPR-Cas9 tracrRNA, and the Alt-R Cas9 
Electroporation enhancer were resuspended in TE buffer to an 100 µM stock solution, 
respectively. Five µl of the guide RNA stock (100 µM) and 5 µl of the Alt-R CRISPR-Cas9 
tracrRNA stock (100 µM) were mixed in a 0.5 ml reaction tube and incubated at 95°C for 
5 min. The mixture was cooled down to RT. For final complex formation, 6 µl of the CRISPR-
RNA mix and 2 µl of the Cas9 Nuclease were mixed in a 1.5 ml tube and incubated for 
20 min at RT. Then, the complex was warmed to 37°C in the incubator. The CRISPR-RNA-
Cas9 complex, the Alt-R Cas9 Electroporation enhancer, the nucleofector solution and the 
HDR template (resuspended in IDTE to 100 µM stock) were mixed in a 1.5 ml reaction tube 





Component  Amount  
Nucleofector solution  82 µl 
Nucleofector supplement  18 µl 
CRISPR-RNA-Cas9 complex   8 µl 
Alt-R Cas9 electroporation enhancer 
(100 µM) 
 1 µl 
HDR template (100 µM)  3 µl 
 
After appropriate mixing, the solution was incubated for 5 min at RT. Before use, it was 
warmed to 37°C.  
4.7.3. Transfection  
iPSCs from the ACT1.10 line were pretreated with 2 µM TZV for 60 min before transfection. 
iPSCs were detached from the plate with Versene and washed off the plate with StemFlex 
medium. Two million iPSCs were transferred into a new 15 ml falcon tube and spun down for 
three min at 200 x g. The supernatant was aspirated and the cells were resuspended in the 
prepared nucleofector mix. The mixture was then transferred to a nucleofector cuvette and 
transfected with program B-016 of the Nucleofector 2b Device. The iPSCs were then diluted 
in 1 ml StemFlex medium and plated equally on three new wells of a 6-well plate with Stem 
Flex/TZV and Penicillin/Streptomycin. To test the efficacy of an HDR template enhancer, we 
added 20 µM and 30 µM HDR template enhancer to two wells of the 6-well plate, 
respectively. One well was not treated with HDR template enhancer and served as negative 
control. The transfected cells were cultured for 48 h at 37°C and 5% CO2. Then, the medium 
was changed to StemFlex medium with 2 µM TZV. On day six after transfection, iPSCs were 
singularized and the rest was harvested for amplicon sequencing and cryo-preserved (4.7.4). 
4.7.4. Singularization of the transfected cells  
In order to obtain single cell colonies, transfected iPSCs were singularized through Versene 
treatment and pipetted up and down for two to four times. iPSCs were counted and 600, 800, 
1000, 1200, 1400, and 1600 cells were seeded onto a well of 6-well plate, respectively. One 
half of the remaining cells was centrifuged for three min at 200 x g, the supernatant 
aspirated, resuspended in freezing medium and cryo-preserved with a Mr. Frosty Freezing 
Container at -80°C. The other half of the remaining cells was centrifuged at 13,000 rpm for 




4.7.5. Picking colonies  
After approximately one week, single iPSC colonies were picked with heat-modified glass 
Pasteur pipettes and each colony was transferred to one well of a 12-well plate, respectively. 
Singularized colonies were cultured with Stem Flex media until they were confluent. 
Confluent colonies were transferred to a well of a 6-well plate and once that was confluent, 
iPSCs were harvested for Sanger sequencing and for cryo-preservation. 
4.7.6. Sanger sequencing 
To test the genomic status of gene-edited iPSC colonies, iPSCs were harvested and sent for 
Sanger sequencing (Microsynth seqlab). iPSCs were harvested from one well of a 6-well 
plate when they were confluent and genomic DNA (gDNA) was isolated as described under 
4.5.2. The region around the SNP was amplified with Rac2-specific primers with PCR (4.5.3), 
and PCR products were reviewed for matching band size and purity with gel electrophoresis 
(4.5.4). Rac2 bands were cut out of the agarose gel and the PCR product was purified with a 
QIAquick gel extraction kit according to the manufacturer’s instructions. The purified product 
was sent to Microsynth seqlab for Sanger sequencing and results were processed with the 
BioEdit software. 
4.8. Telomere length and TERT overexpression 
4.8.1. Telomere length assay with PCR 
Telomere length was compared between different iPSC lines and between iPSCs and iPSC-
CMs of the same line with PCR as reported by Cawthon (Cawthon, 2002). In this approach, 
the Telomere-to-Single Copy Gene (T/S) ratio is determined, which is proportional to the 
average telomere length in a cell (Cawthon, 2002). The described protocol was optimized 
following reported improvements (Martinez-Delgado et al., 2011). Telomere length assays 
were carried out by Shambhabi Chatterjee in the group of Dr. Chrisitan Bär at the 
Medizinische Hochschule Hannover. The exact procedure was recently described in detail by 
our collaborators (Chatterjee et al., 2018). In short, DNA from iPSC and iPSC-CMs was 
extracted and amplified with primers for the telomere repeat sequence and a reference single 
copy gene (36B4) by PCR. The relative telomere length was determined by the ratio of the 
telomere repeat sequence to the reference single copy gene. 
4.8.2. Telomere length assay with quantitative fluorescent in situ hybridization  
Our group prepared the cells for the quantitative fluorescent in situ hybridization (qFISH) 
analysis: iPSCs and iPSC-CMs were detached with Versene solution and trypsin/EDTA, 
respectively. For each cell type two concentrations were prepared. For iPSCs one solution 
contained 7.5 x 105 cells/ml and the other 5 x 105 cells/ml. For iPSC-CMs the concentrations 
were 1 x 106 cells/ml and 7.5 x 105 cells/ml. 100 µl of each solution were spun on Superfrost 
microscope slides with white filter cards in a Cytospin 4 centrifuge (Thermo Scientific) at 800 




Shambhabi Chatterjee in the group of Dr. Chrisitan Bär at the Medizinische Hochschule 
Hannover according to previously reported protocols (Canela et al., 2007). In short, cells 
were incubated with a hybridization solution containing a fluorophore-conjugated peptide 
nucleic acid probe. After hybridization, samples were imaged with a fluorescent microscope. 
Quantitative image analysis of fluorescence intensities was applied to calculate the relative 
telomere length. 
4.8.3. AAV6 treatment 
TERT overexpression in the iPSC-CMs was induced with AAV6 vectors. AAV6 vectors were 
produced in the group of Dr. Christian Bär at the Medizinische Hochschule Hannover. AAV6 
human TERT (hTERT) contains cytomegalovirus (CMV) promoter and enhancer sequences. 
Furthermore, it contains ampicillin resistance and the sequence is flanked by AAV2 inverted 
terminal repeats (ITRs; Figure 4-1). Similarly, AAV6 empty vector is also regulated through a 
CMV promoter and enhancer. It has ampicillin resistance, and AAV2 ITRs (Figure 4-2). 
Instead of the hTERT sequence, the empty vector has a poly(A) signal (Figure 4-2). To 
correctly calculate the multiplicity of infection (MOI), iPSC-CMs were counted and 5 x 105 
cells/well were seeded onto a 6-well-plate. Three days later, the medium was changed to 
cardio culture medium (2 ml/well) and another 24 h later AAV6 at an MOI of 1 x 104 units/cell 












After three days, the medium was changed to virus-free cardio culture medium and iPSC-
CMs were cultured for seven days to recover from virus treatment. After the recovery period, 
cells were treated with 0.5 µM DOX for three days and subsequently the apoptosis and the 
Amplex red assays were carried out respectively. 
4.8.4. Apoptosis assay with flow cytometry 
The rate of apoptosis in our samples was observed with the APC-Annexin V apoptosis 
detection kit. The cells were prepared according to the manufacturer's protocol. Briefly, for 
each, condition we used 1.5 x 105 iPSC-CMs. iPSC-CMs were washed with PBS and 
incubated with 0.25% Trypsin/EDTA for 12 min to disassociate. To get a complete picture of 
apoptosis and necrosis, the supernatant was transferred into a conical tube prepared with 
500 µl FCS. The cells were segregated from the supernatant through centrifugation at 
200 x g for 3 min. The samples were resuspended in 1 ml PBS and subsequently washed 
three times. After the last washing step, iPSC-CMs were resuspended in Annexin V binding 
buffer. 100 µl of the suspension were transferred into one of four flow cytometry tubes, 




according to the following scheme: control (none), Annexin single staining (Annexin V), PI 
single staining (PI), and double staining (Annexin + PI). The staining-iPSC-CM solutions 
were incubated for 15 min in the dark at RT. Afterwards, 400 µl of Annexin V binding buffer 
were added to each tube and the samples were measured with a BD FACS Canto II (BD 
Biosciences) flow cytometer. Unstained and single stainings served as references for 
negative and Annexin-/PI-positive cell populations, respectively. Flow cytometry data was 
analyzed with Flowing Software 2.0. 
4.8.5. Extracellular ROS measurement 
Extracellular H2O2 in the supernatant of iPSC-CMs was assessed with an Amplex red kit 
(Zhou et al., 1997). In preparation for the assay, H2O2 in increasing concentrations from 0 µM 
to 1 µM (10 µM H2O2 stock solution diluted in Amplex red reaction buffer) was pipetted into 
the first row of a black 96-well plate, as depicted in Table 4-5. The values of these wells were 
used to calculate a standard curve. H2O2 values were calculated according to the standard 
curve measurements. In total, 5 x 105 iPSC-CMs per well were cultured in a 6-well plate and 
treated with DOX and AAV6 as indicated. On the day of the assay, iPSC-CMs were washed 
twice with reaction buffer and incubated with 320 µl working solution 1 for 30 min in the dark 
at 37°C. Immediately after treatment of the cells, 50 µl of working solution 2 were added to 
each well of the H2O2 standards, and the plate was incubated together with the iPSC-CMs for 
30 min in the dark at 37°C. 
Table	4-5:	H2O2	standard	for	Amplex	red	measurement	


























After the incubation period, working solution 1 from each well was transferred into a new 
reaction tube. From each tube, 100 µl of solution were pipetted into three wells of the black 
96-well plate, respectively. Luminescence was measured with a Mithras² LB 943 plate reader 
(Berthold Technologies, Bad Wildbad, Germany) at RT with the following settings: 
fluorescence was measured at 540 nm excitation (filter F540) and 620 nm emission (filter 
Em600/10) for 0.1 sec with 0.2 sec delay and 40% of the lamp energy. Measurement values 
were processed with Microsoft excel and plotted with Graphpad Prism 7.  
4.9. Immunocytochemistry staining 
Expression of cellular proteins was shown with immunocytochemistry staining as described 
earlier by our group (Borchert et al., 2017; Haupt, 2018). In short, iPSCs or iPSC-CMs were 
cultured on glass cover slips, fixed with Histofix for 20 min at RT and blocked with 




were permeabilized with 0.1% Triton X-100 for 10 min at RT. All samples were incubated 
with the respective primary antibody overnight at 4°C in a humidified chamber. The following 
day, the glass cover slips were washed three times in PBS and then incubated with a 
corresponding secondary antibody for 1 h at 37°C. Afterwards, the cover slips were washed 
three times in PBS and then the nuclei were stained with DAPI for 10 min at RT in the dark. 
Then, the cover slips were washed three times in PBS and once in Millipore water. Finally, 
the cover slips were mounted onto microscopy slides with Vectashield mounting medium and 
sealed with nail polish. Images were captured with a Zeiss Axio Observer.Z1 microscope and 
a Zeiss AxioCam MRm 1.4MP camera. Detailed information about the used antibodies is 
listed in	Table 3-4. 
4.10. Cell size 
Cell size was determined with CASY cell counter, which allowed fast three-dimensional 
measuring of iPSC-CMs. 
Ten days before the assay, 25,000 iPSC-CMs were seeded onto each well of a 12-well plate 
and cultured in cardio culture medium under standard conditions. On the day of the assay, 
brightfield images of each well were captured for reference. Then, iPSC-CMs were detached 
from the plate with trypsin/EDTA, diluted in CASY buffer and measured with the CASY 
device. The limits for detection were set to 14.99 µm (minimum) and 45.02 µm (maximum) 
according to the expected size range for iPSC-CMs. Each sample from an individual well 
was counted three times, and mean diameter and mean volume were displayed in excel files 
and plotted with GraphPad Prism 7. Our former group member Ahmed Wagdi automated 
parts of the analysis with Python scripts.  
4.11. Analysis of sarcomeric organization 
The myofilament structure was observed with α-actinin staining (see Immunocytochemistry	
staining). To assess its degree of organization, tubular structures in the images were 
emphasized with the "Tubeness" plugin of the FIJI software. Then we applied the fast Fourier 
transform algorithm (FFTA). After applying FFTA, the frequency domains were radially 
integrated with "Radial Profile Plot" from Paul Baggethun (as in Ball et al., 2015; Chlanda et 
al., 2016; Taffoni et al., 2019). These steps were performed by a macro for FIJI, which was 
written and extended by the former group members Thomas Borchert and Dr. Luis Haupt 
(Haupt, 2018). A Python script written by Ahmed Wagdi automated and accelerated the 
process. The resulting intensity profiles were analyzed with Lab Chart software (BD 
Instruments). The relative amplitude of the first peak positively correlates with the regularity 




4.12. Statistical analysis 
Individual data points are depicted as dots, with boxes indicating the mean +/- standard error 
of the mean (SEM). Outliers were identified with ROUT (robust regression followed by outlier 
identification) (Motulsky and Brown, 2006), Q = 1 with Prism (GraphPad). Statistical 
significance of data sets consisting of two groups was tested with a two-tailed Student’s t-
test. Data sets with more than two groups were tested with one-way analysis of variance 
(ANOVA) and multiple comparisons between treatments were corrected according to Tukey 
and multiple comparisons between patients were corrected according to Sidak. Data sets 
where two factors were influenced were tested with two-way ANOVA. Multiple comparisons 
of two-way ANOVAs were corrected according to Tukey or Sidak. Significances were 
indicated with *=p < 0.05; **=p < 0.01; ***=p < 0.001. Exact p values and confidence intervals 
are listed in the appendix. In all analyses, Prism versions 7 and 8 (GraphPad) were used. 
4.13. Software for representation of data 
Graphs were plotted with GraphPad Prism versions 7 and 8. Figure 4-1 and Figure 4-2 were 
created with DNADynamo. Visualization of sequencing data was performed with BioEdit 
(Figure 5-7 and Figure 5-13). Figure 2-2, Figure 2-3, and Figure 5-8 were designed on the 






5.1. Basic impact of DOX 
Other groups and we have shown that ACT can be modeled with iPSC-CMs. ACT-iPSC-CMs 
have shown a higher susceptibility to the damaging effects of DOX compared to control-
iPSC-CMs. The differences are manifested in higher ROS production, disruption of 
sarcomeric regularity, increased rates of apoptosis, and aberrant calcium handling (Burridge 
et al., 2016; Haupt, 2018). 
5.1.1. Resorption and retention of DOX in an ACT model 
In order to accurately describe the molecular mechanisms underlying the previously 
mentioned changes, it is important to understand the resorption of DOX. To date, there have 
been no publications addressing subcellular and time-dependent distributions of DOX in 
human cardiomyocytes. The initial aim of this study was to identify resorption rates, possible 
maximal resorption doses, retention, and subcellular distribution of the DOX in iPSC-CMs. 
Therefore, we used the previously characterized iPSC-CM cohort from a former study in our 
lab (Haupt, 2018). Briefly, five patients were selected from the RICOVER-60 trial, which 
investigated the outcome of anthracycline treatment of elderly B-cell lymphoma patients 
(Pfreundschuh et al., 2008). Three of the cancer patients had developed ACT and are 
assigned here as ACT patients. Two other patients, who had received similar accumulative 
doses of DOX, did not develop ACT and served as control patients. The three ACT patients 
carried homozygous or heterozygous SNPs in genes encoding subunits of Nox2. The two 
control patients had wild-type (wt) sequences at these positions. These SNPs have been 
linked to the occurrence of ACT (Wojnowski et al., 2005), and were also described in the 
RICOVER-60 trial (Reichwagen et al., 2015). The five selected patients donated skin 
biopsies that were used to extract skin fibroblasts. These were reprogrammed into iPSCs by 
introducing the Yamanaka factors with a Sendai virus. Characterized iPSCs were cultured in 
feeder-free culture and differentiated into iPSC-CMs as described previously (Borchert et al., 
2017; Haupt, 2018). The resulting iPSC-CMs from ACT patients and iPSC-CMs from the 
controls showed patient-specific genetic backgrounds and were used in this study to reveal 
potential differences between the two groups regarding their reactions to DOX exposure.  
iPSC-CMs of ACT patients and controls were treated with DOX for different periods or with 
various concentrations. Immediately after the respective treatment period, iPSC-CMs were 
lysed and the samples were processed for HPLC measurement. To address reported long-
term damages caused by DOX (Middleman et al., 1971; Serrano et al., 1999), in one part of 
the study, iPSC-CMs were given time to recover from the treatment. Afterwards, the iPSC-
CMs were washed with PBS, harvested with acetonitrile and the amount of intracellular DOX 
was determined with HPLC. As a reference, DOX diluted in PBS was also injected, which 




nm emission). HPLC peak analysis was performed with Chromeleon 7 software and the area 
under the curve was measured for each peak. 
5.1.1.1. Concentration-dependent DOX resorption 
From previous studies in the lab, we know that DOX exposure leads to increased extra- and 
intracellular levels of ROS, aberrant calcium handling, sarcomeric irregularity and increased 
rates of apoptosis in iPSC-CMs from both groups, ACT patients and control patients (Haupt, 
2018). Regarding ROS levels, sarcomeric regularity, and apoptosis, the observed detrimental 
effects were enhanced with increasing DOX concentrations (Haupt, 2018). Intracellular H2O2 
levels in both groups doubled after treatment with 5 µM DOX compared to treatment with 
0.25 µM DOX (Haupt, 2018). Apoptosis rates in both groups were about 1.5 times higher with 
1 µM DOX as compared to 0.5 µM DOX when treated for 24 h (Haupt, 2018). After treatment 
for 72 h, apoptosis rates in both groups were approximately three times higher with 1 µM 
DOX as compared to 0.5 µM DOX. Furthermore, the apoptosis rate in both groups tripled 
after 72 h with 1 µM DOX, compared to 24 h with the same concentration (Haupt, 2018). 
These results showed that DOX-triggered effects in iPSC-CMs are dose and time dependent. 
However, it is still unknown whether DOX accumulates in iPSC-CMs and intracellular DOX 
levels depend on treatment time and concentration. 
	
Figure	5-1:	Intracellular	DOX	levels	in	iPSC-CMs	increased	with	rising	DOX	concentrations.	
The	 intracellular	DOX	concentration	 increased	with	higher	 treatment	 concentrations	of	DOX	 in	 the	
culture	medium.	A:	 Intracellular	DOX	values	 increased	with	higher	DOX	concentrations	 in	both	ACT	
patient	(blue	columns)	and	control	(black	columns)	groups.	At	concentrations	of	1	µM	and	5	µM	DOX,	
the	 intracellular	DOX	content	was	higher	 in	ACT-iPSC-CMs	compared	to	control	 iPSC-CMs.	B:	When	
values	were	normalized	to	the	1	µM	treatment	conditions,	 intracellular	DOX	levels	 in	ACT-iPSC-CMs	
were	significantly	higher	at	1	µM	DOX	compared	to	untreated.	Untr=untreated.	AU=	arbitrary	unit.	n	
=	 one	 independent	 iPSC-CM	 differentiation	 experiment.	 ACT	 patient:	 n=	 five	 differentiations	 from	







To determine the resorption of DOX, iPSC-CMs were challenged with various DOX 
concentrations from 0.1 µM to 5 µM DOX in the culture medium for 24 h at standard cell 
culture conditions (37°C, 5% CO2). The results show that intracellular DOX concentrations 
increased with rising DOX treatment concentrations (Figure 5-1A). Notably, the increase of 
intracellular DOX was highly associated with DOX treatment concentrations, e.g. 1 µM DOX 
in ACT-iPSC-CMs resulted on average in an area under the curve value of 58,598, which is 
close to double the value of 0.5 µM (30,120), and approximately a fifth of the value of 5 µM 
(334,208). DOX was detectable at the lowest tested media concentration of 100 nM DOX 
and did not reach a plateau in the tested range up to 5 µM (Figure 5-1A). Although not 
significant, DOX levels were higher in ACT-iPSC-CMs compared to control-iPSC-CMs under 
nearly all tested concentrations. When normalized to 1 µM DOX, the intracellular increase in 
DOX concentration reached significance at 1 µM DOX in the ACT patient group compared to 
the untreated iPSCs (Figure 5-1B). Comparing normalized values, intracellular DOX 
concentrations were significantly higher in control patients than in ACT patients at 5 µM 
DOX. While the absolute DOX levels were higher in ACT-iPSC-CMs compared to control-
iPSC-CMs, the normalized values show that the correlation to treatment concentrations is 
prominent in both groups (Figure 5-1B). 
5.1.1.2. Time-dependent DOX resorption 
To estimate the kinetics of DOX resorption, iPSC-CMs from both groups were challenged 
with 1 µM DOX and cultured in standard conditions for time periods between 30 min to 72 h. 
Already after 30 min, DOX was detectable in iPSC-CMs of both groups (Figure 5-2A). After 
2 h and 6 h of treatment, DOX values were significantly higher in the control group compared 
to untreated iPSC-CMs, whereas the absolute DOX values were higher in the ACT patient 
group compared to controls. The intracellular amount of DOX increased with treatment time 
and reached its peak after 48 h. After 72 h of treatment, the values decreased and were 






Intracellular	 DOX	 concentration	 increased	with	 longer	 treatment	 time	 of	 1	µM	DOX	 in	 the	 culture	




differentiation	 experiment.	 ACT	 patients:	 n	 =	 four	 differentiations	 from	 two	 cell	 lines	 from	 one	
patient.	 Control	 patients:	 n	 =	 four	 differentiations	 from	 two	 cell	 lines	 from	one	 patient.	 Statistical	
analysis	was	performed	with	two-way	ANOVA	or	mixed-effects	analysis.	P	values	are	represented	as	
followed:	p	>0.05	=	*;	p	>0.01	=	**;	p	>0.005	=	***.	Bars	indicate	mean	values	+/-	SEM.	
Normalization to the 24 h DOX treatment time point shows that the kinetics of intracellular 
DOX resorption was comparable in ACT- and control-iPSC-CMs (Figure 5-2B). DOX levels at 
the 24 h time point were significantly higher compared to untreated iPSC-CMs in both ACT- 
and control-iPSC-CMs (Figure 5-2B). 
5.1.1.3. DOX content after washout 
Chronic ACT can manifest itself many years or even decades after cancer treatment 
(reviewed by Minotti et al., 2004). It is conceivable that a small amount of DOX remains in 
cardiomyocytes over a long period of time; hence, continuously causing damage that 
becomes apparent in the long term. To test this hypothesis, iPSC-CMs were treated with 
1 µM DOX for 24 h and cultured under standard conditions for three days and seven days 
(Figure 5-3A). After the treatment period (time point 0), the medium was removed and the 
iPSC-CMs were cultured in regular cardio culture medium without DOX. For iPSC-CMs that 







Intracellular	 DOX	 levels	 decreased	 after	 one	 day	 of	 recovery	 and	 reached	 the	 detection	 threshold	




CMs	 (black	 columns).	 C:	 When	 normalized	 to	 time	 point	 zero	 (one	 day	 of	 DOX	 treatment,	 0	 h	
recovery),	 control-iPSC-CMs	 showed	a	 significant	 decrease	 after	 three	days.	 In	ACT-iPSC-CMs,	DOX	
was	 significantly	 decreased	 after	 seven	days	 of	 recovery.	 AU=	 arbitrary	 unit.	 n	 =	 one	 independent	
iPSC-cardiomyocyte	differentiation	experiment.	ACT	patient:	n=	 four	differentiations	 from	two	 iPSC	




Three days of recovery resulted in a significant decrease of intracellular DOX of 
approximately 75% in both the ACT- and control group (Figure 5-3B). After seven days of 
recovery, the abundance of DOX was below or close to the detection limit in both groups 
(Figure 5-3B). Notably, when values were normalized to time point 0, the decrease of 
intracellular DOX became significant after three days in the control group (Figure 5-3C), 
whereas a similar (25% in control vs. 17.3% in ACT) significant decrease in intracellular DOX 
was reached in ACT-iPSC-CMs after seven days of recovery (Figure 5-3C).  
These results indicate that a significant DOX amount did not remain in the iPSC-CMs for 
extended periods and that the washout was faster in iPSC-CMs from control patients than in 
iPSC-CMs from ACT patients. This supports the ‘hit-and-run’ model of DOX-induced 
damage, where DOX induces changes that continue to affect the cell past the period when 
DOX is present (Vesell and Passananti, 1971; Cowgill et al., 2019). In line with that, our 
group has shown that DOX treatment leads to enhanced extracellular H2O2 levels for up to 
three weeks after treatment (Haupt, 2018). Immediately after 24 h of 0.25 µM DOX 
treatment, H2O2 production in ACT-iPSC-CMs and control-iPSC-CMs was increased by two-
fold (Haupt, 2018). One week after DOX treatment, H2O2 levels were increased 3- to 4-fold 
and three weeks after DOX treatment, the increase in H2O2 production was still two-fold 
compared to untreated iPSC-CMs (Haupt, 2018). Taken together, we have shown that DOX 
is cleared from iPSC-CMs within one week, while DOX-induced effects, such as enhanced 
H2O2 production, remain for several weeks. 
5.1.1.4. Subcellular distribution of DOX 
DOX is described to bind to the mitochondrial phospholipid cardiolipin, hence, we expected 
the drug to accumulate prevalently in close proximity to mitochondria rather than in other cell 
compartments (Nicolay et al., 1984; Goormaghtigh et al., 1990; Aryal and Rao, 2016). Using 
differential ultracentrifugation, we separated the mitochondrial and nucleus fraction, termed 
here mito fraction, from the membrane fraction and cytoplasm (Laurindo et al., 2002). The 






Three	 distinct	 cell	 fractions	 were	 analyzed	 with	 HPLC.	A:	 Measuring	 total	 DOX	 content,	 the	 mito	
fraction	 showed	 the	 highest	 DOX	 levels	 among	 the	 three	 fractions.	 The	 DOX	 levels	 in	 the	 mito	
fractions	were	significantly	higher	 than	 in	 the	membrane	 fractions.	B:	The	ring	charts	 illustrate	 the	
distribution	of	DOX	over	the	three	fractions	in	the	ACT-	and	control	group.	In	ACT-iPSC-CMs,	51%	of	
DOX	 was	 detected	 in	 the	 mito	 fraction.	 In	 control-iPSC-CMs,	 60%	 of	 DOX	 was	 found	 in	 the	 mito	
fraction.	 AU=	 arbitrary	 unit.	 Statistical	 analysis	 was	 performed	 with	 two-way	 ANOVA.	 n=	 seven	
independent	 differentiations	 from	 two	 cell	 lines	 from	 two	 patients	 (ACT-iPSC-CMs),	 n	 =	 six	
independent	 differentiations	 from	 two	 cell	 lines	 from	 two	 patients	 (control-iPSC-CMs).	 For	 A,	
different	 shades	 of	 blue	 and	 grey	 indicate	 data	 points	 from	 different	 patients.	 The	 p	 value	 was	
represented	as	followed:	p	0.04	=	*.	Horizontal	bars	indicate	the	mean	+/-	SEM.	
Mean DOX levels were higher in the mito fraction compared to membrane or cytoplasmic 
fraction in both ACT- and control-iPSC-CMs (Figure 5-4A). DOX levels in the mito fractions 
were significantly higher than in the membrane fractions (Figure 5-4A, appendix). For all 
tested fractions (mito, membranes, cytoplasm), the mean DOX levels were higher in ACT-
iPSC-CMs compared to control-iPSC-CMs. Focusing on the distribution of DOX among the 
three fractions, in both groups the highest percentage of DOX was detected in the mito 
fraction, followed by the cytoplasm, and the least in the membrane fraction (Figure 5-4A). In 
detail, in the ACT patient group, 51% of DOX was detected in the mito fraction, 30% in the 
cytoplasm and 19% in the membrane fraction (Figure 5-4B). A similar DOX distribution could 
be observed in the control-iPSC-CMs with 60% of the whole amount of DOX in the mito, 28% 
in the cytoplasm and 12% in the membrane fraction (Figure 5-4B). Comparing these 
percentages between the groups, a smaller mitochondrial percentage was observed in the 
ACT patient group (51%) than in the control patient group (60%). Furthermore, in both 
groups less than 20% of DOX was detected in the membrane fraction (19% in the ACT 
patient group and 12% in the control patient group). It should be noted that the membrane-
fraction pellets were considerably smaller in size and volume than the pellets containing the 










the	 ACT-iPSC-CMs,	 DOX	was	 distributed	 evenly	 between	 the	membrane	 and	 the	 cytosolic	 fraction	
(both	38%),	with	less	DOX	in	the	mito	fraction	(24%).	In	the	control-iPSC-CMs	nearly	half	of	DOX	was	
detected	in	the	mito	fraction	(47%).	The	rest	of	the	DOX	was	distributed	almost	equally	between	the	
membrane	 (29%)	 and	 the	 cytosolic	 fraction	 (24%).	 AU=	 arbitrary	 unit.	 Statistical	 analysis	 was	
performed	with	two-way	ANOVA.	n=	7	independent	differentiations	from	2	cell	lines	from	2	patients	
(ACT	 patient	 group),	 n	 =	 6	 independent	 differentiations	 from	 2	 cell	 lines	 from	 2	 patients	 (Control	
patient	 group).	 Different	 shades	 of	 blue	 and	 grey	 indicate	 data	 points	 from	different	 patients	 (A).	
Horizontal	bars	indicate	the	mean	+/-	SEM.	
When normalized to the protein content, DOX distribution occurred relatively evenly 
throughout the fractions. Higher levels of DOX were detected in ACT patients compared to 
control patients, with an accumulative value of 898 [AU] in ACT-iPSC-CMs compared to 319 
[AU] in control-iPSC-CMs (Figure 5-5A). In each of the three fractions, the DOX value was 
higher in ACT-iPSC-CMs than in control-iPSC-CMs. In the mito fraction, the values were 217 
in ACT vs. 151 in control; in the membrane fraction 344 in ACT vs 94 in control; and in the 
cytoplasmic fraction 337 in ACT vs 76 in control (Figure 5-5A). In the ACT patient group, 
DOX was distributed evenly between the membrane and the cytosolic fraction (both 38%), 
with less DOX in the mito fraction (24%). In the control patient group, nearly half of the total 
amount of DOX was detected in the mito fraction (47%). DOX levels in the membrane and 
cytosolic fractions of the control patient group were similar (29% in membrane fraction and 
24% in the cytoplasm). While in the control patient group a high level of intracellular DOX 
was assigned to the mito fraction (47%), the mean percentage of this fraction was lower in 




in ACT-iPSC-CMs compared to control-iPSC-CMs. In conclusion, intracellular DOX 
concentrations differed between ACT-iPSC-CMs and control-iPSC-CMs. 
5.2. Effects of DOX treatment on mRNA translation 
Chronic DOX treatment can have a profound impact on the gene expression profile of 
cardiac cells (Berthiaume and Wallace, 2007; Holmgren et al., 2015, 2018; Li et al., 2019). 
Our group has previously found that a set of the investigated genes, including genes 
encoding for proteins that compose sarcomeric structure or act in calcium homeostasis, were 
down-regulated after DOX treatment (Haupt, 2018). Therefore, we aimed to determine to 
what extent DOX treatment would have a global effect on mRNA translation in an iPSC-CM 
ACT model. To investigate this question, we applied the SUnSET approach to detect 
potential changes in mRNA translation (Schmidt et al., 2009) and incubated DOX-treated 
iPSC-CMs and untreated iPSC-CMs with 1 µM puromycin for 20 min at 37°C prior to lysis. 








mRNA	 translation	 was	 investigated	 with	 Western	 blot	 after	 puromycin	 treatment.	 Abundance	 of	
puromycin	 positively	 correlated	 with	 translation	 rates.	 A:	 Representative	 images	 of	 puromycin	
abundance	 after	 Western	 blotting.	 Positive	 control	 (Pos	 ctrl):	 Lysate	 from	 H9c2	 human	
cardiomyoblast	 cell	 line	 incubated	 with	 1	 µM	 puromycin	 for	 30	 min.	 Negative	 control	 (Neg	 ctrl):	
lysate	 from	 DOX-treated	 control	 patient	 2	 iPSC-CMs	 without	 puromycin.	 As	 reference	 proteins	
GAPDH	(left),	β-tubulin	(center),	and	actin	(right)	were	used.	B:	Signal	intensities	per	patient	with	and	
without	DOX	treatment.	Values	did	not	differ	significantly	between	any	cell	 lines.	C:	DOX	treatment	
significantly	 reduced	puromycin	 levels	 in	all	 tested	 iPSC-CMs	 from	both	ACT-iPSC-CMs	and	control-
iPSC-CMs.	 The	 reduction	was	 similar	 between	 the	 groups.	D:	 Fold	 change	of	 puromycin	 intensities	
per	 iPSC	 line	with	DOX	 treatment	 normalized	 to	matched	 untreated	 values.	 DOX	 treatment	 had	 a	





Western blots of DOX-treated iPSC-CMs showed lower signals for puromycin compared to 




iPSC-CMs from ACT patient 2 without puromycin treatment and found one faint unspecific 
band (Figure 5-6A), while the positive control (internal control: lysate from H9c2 cells treated 
with 1 µM puromycin for 30 min) showed a strong signal. All quantification values came from 
two blots, in which actin was used as reference (Figure 5-6B-D). The representative blots in 
Figure 5-6A are partially from earlier blots, where β-tubulin or GAPDH were used as 
reference. Quantified signal intensities confirmed a reduction in signal after DOX treatment, 
which was consistent throughout all tested cell lines (Figure 5-6B). Signal intensity and 
reduction of signal were in a similar range across all cell lines and did not differ significantly. 
Overall, DOX treatment led to a significant decrease of mRNA translation (Figure 5-6C). The 
decrease in translation after DOX treatment was significant in both ACT- and control-iPSC-
CMs (Figure 5-6D). There was no significant difference in mean signal reduction between the 
ACT patient and control patient group (Figure 5-6D), indicating that the DOX-induced 
decrease in translational processes is similar in ACT- and control-iPSC-CMs. 
5.3. Correcting a SNP with CRISPR/Cas9 gene editing 
ACT patients and controls were selected according to the presence or absence of specific 
SNPs in genes that encode for subunits of the NADHPH oxidase. In this study, we focused 
on the SNP rs13058338 in the RAC2 gene (see 2.1.3). This genetic variant was described in 
clinical studies on the role of this SNP in ACT (Wojnowski et al., 2005; Reichwagen et al., 
2015; Vulsteke et al., 2015; Leong et al., 2017). Table 5-1 presents an overview of 
characteristics of rs13058338 in the RAC2 gene and shows the genotypes of the ACT cell 
lines in our group. A SNP-corrected ACT-iPSC line and its comparison to native iPSC-CMs 
from both ACT as well as control patients may reveal whether this polymorphism in the 
RAC2 gene is mechanistically linked to ACT. 
There are several approaches that could be used to investigate the impact of the described 
SNP on ACT development. First, one could test the activity of activated downstream 
complexes. In the case of ACT, Nox2 is the most promising downstream protein complex. Its 
activity can be either tested by complex assembly at the cell membrane or by direct 
measurement of its main product, superoxide. The low endogenous abundance of the Nox2 
subunits p47phox and gp91phox in the iPSC-CMs made it difficult to precisely determine 
protein levels and their assembly by means of Western blotting. Instead, we conducted 
superoxide measurements of iPSC-CM membrane fractions with the ROS-sensing probe 
DHE. Assessment of the functional properties with the DHE probe was hampered by cross-
reactions with DOX (data not shown), and therefore was unable to produce reliable data. In 
another approach to assess the importance of the described SNP in the development of 
ACT, we aimed to correct the SNP in an ACT-iPSC line by reverting the polymorphism to the 




homeostasis, in the corrected iPSC-CMs may give hints whether these cells behave more 
like iPSC-CMs from the ACT patient group or from the control group. 
Table	5-1:	Overview	of	the	single-nucleotide	polymorphism	rs13058338	in	the	RAC2	gene.	
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AA AT AT TT TT 
	
5.3.1. SNP confirmation and primer validation 
Before attempting to correct the SNP in an ACT-iPSC line, we aimed to confirm again the 
presence of this aberration in the iPSC lines. Therefore, iPSCs from ACT patient 1 cell line 
10 (ACT 1.10), ACT patient 2 cell line 14 (ACT 2.14), as well as control patient 1 cell line 2 
(ACT K 1.2), and control patient 2 cell line 9 (ACT K 2.9) were collected, their gDNA 







Sanger sequencing (carried out by Microsynth AG, Balgach, Switzerland) confirmed that 
iPSCs of ACT patient 1 carried a homozygous mutation in RAC2 (SNP rs13058338) with AA 




control patient 1 and control patient 2 showed a wt sequence at these positions (TT; Figure 
5-7). 
5.3.2. Design of HDR templates and guide RNAs 
The aim of genome editing was to correct the SNP in RAC2 to the respective wt sequence. 
To specifically target RAC2, a gRNA and an HDR template were designed (Figure 5-8). Two 
different online tools were used to design the gRNA sequence and to select the most 
promising outputs. Initially, the ‘Custom Alt-R CRISPR-Cas9 guide RNA’ tool was used, 
which is provided by Integrated DNA Technologies (IDT; Coralville, IA, USA). As a second 
parameter, CRISPOR.org was used (Concordet and Haeussler, 2018). The binding 
sequence for the gRNA, the sequence for the HDR template, and the predicted scores from 
both tools are depicted in Figure 5-8. The selected gRNA was chosen because it cuts close 
to the SNP (five base pairs [bps] upstream) and had a low off-target score. The off-target 
score includes potential mismatches in which the gRNA binds to sequences that differ in one 
or more bps from the gRNA sequence. For zero and one mismatches, the chosen gRNA is 
predicted to bind to no sequences other than the target sequence. For any two mismatches, 
the gRNA is predicted to potentially bind to four off-target sequences and for three 
mismatches to 35. This favorable off-target score and the proximity of the cutting site to the 
SNP determined the choice of gRNA and the derived HDR template. 
	





A:	 The	 gRNA	binding	 sequence	 contained	 the	 SNP	 (red	box),	which	was	 located	 seven	nucleotides	
downstream	of	the	next	PAM	site	(yellow	box).	The	Cas9	cutting	site	was	five	base	pairs	upstream	of	
the	 SNP.	 Prediction	 scores	 of	 two	 independent	 databases	 calculated	 low	 probabilities	 for	
mismatches.	 A	mismatch	 of	 ‘2’	means	 that	 the	 guide	 RNA	 is	 expected	 to	 bind	 to	 a	 sequence	 that	
differs	 in	 two	bases	 from	 the	 intended	binding	 sequence.	 The	CRISPOR	 score	 indicates	 that	 in	 this	
case,	there	are	four	off-site	targets.	For	any	three	mismatches,	there	are	35	targets,	etc.	B:	The	HDR	
template	 contained	 45	 nucleotides	 on	 each	 side	 of	 the	 SNP.	 The	 mutant	 nucleotide	 itself	 was	
swapped	with	 the	wild-type	nucleotide	 (T	 for	A,	 red	box).	 To	 limit	Cas9	activity,	 the	PAM	site	was	
destroyed	with	 a	 synonymous	mutation	 (G	 for	 C,	 yellow	 box).	 Since	 the	 PAM	 site	 is	 located	 in	 an	
intronic	 region,	 no	 coding	 triplets	 are	 defined.	 PAM:	 Protospacer	 adjacent	 motif.	 SNP:	 Single-
nucleotide	polymorphism.	
5.3.3. iPSC electroporation and culture with HDR enhancer 
The CRISPR-RNA-Cas9 complex was transfected into iPSCs using electroporation. Two 
days prior to transfection, iPSCs from the ACT 1.10 line were seeded out and cultured in 
StemFlex medium under standard conditions (Figure 5-9). On day zero, iPSCs were 
electroporated with the CRISPR-RNA-Cas9 complex, gRNA, and the Rac2-specific HDR 
template, which resulted in an iPSC line named ACT 1.10_R. Cas9-induced DSBs can be 
resolved through both NHEJ and HDR, although the predominant repair mechanism is NHEJ 
(Frit et al., 2014). The integration of the HDR template relies on the HDR repair pathway. To 
increase the rate of DSB repair through HDR, we tested the small molecule reagent ‘Alt-R 
HDR enhancer’ (IDT, Coralville, IA, USA), which has been described by the manufacturer to 
enhance gene editing by 50%-400% in different human cell lines (Schubert et al., 2018). The 
HDR enhancer was added directly to the culture medium after electroporation for 24 h at two 
different concentrations (Figure 5-9). Since the HDR enhancer is dissolved in DMSO, the 
highest recommended dose is 30 µM to avoid cytotoxicity. We used 20 µM and 30 µM, 
respectively, and cultured an additional well of electroporated iPSCs without HDR enhancer. 
After one day, the HDR enhancer was removed and the iPSCs were cultured in StemFlex 





On day one after electroporation, iPSCs were examined for growth, density, and degree of 
cell debris in the culture medium. iPSCs of the non-transfected control were attached to the 




the plate (Figure 5-10, center left), where cells appear as bright, round balls. iPSCs which 
were treated with 20 µM HDR enhancer showed even lower cell density (Figure 5-10, center 
right) and visibly more debris in the culture medium that was even more prominent with an 
HDR enhancer concentration of 30 µM (Figure 5-10, right). Overall, addition of HDR 
enhancer led to more cell debris, indicating elevated cell death and resulted in a lower 
number of cells. More important than cell numbers was the rate of successful editing, which 
was estimated with Amplicon sequencing. 
		
Figure	 5-10:	 Representative	 bright	 field	 images	 of	 iPSCs	 one	 day	 after	 electroporation	 for	
CRISPR/Cas9	gene	editing.	
To	 enhance	 efficiency	 of	 the	HDR,	 a	 HDR	 enhancer	 solution	was	 added	 to	 the	 culture	medium	 at	
concentrations	 of	 20	 µM	and	 30	 µM.	Non-transfected	 iPSCs	 showed	 no	 signs	 of	 distress	 (far	 left),	
while	 transfected	 iPSCs	detached	 from	the	plate	 (center	 left).	HDR	enhancer-treated	 iPSCs	showed	
lower	 cell	 density	 and	 visibly	 more	 debris	 in	 the	 culture	 medium	 (center	 and	 far	 right).	 10x	
magnification,	scale	bars	=	20	µm.	
5.3.4. Amplicon sequencing 
Sanger sequencing is not suitable to detect SNPs in mixed samples, because the low 
number of reads does not allow a distinction between reading errors and the actual 
nucleotide polymorphism. Sequencing with a higher number of reads, so-called ultra-deep 
sequencing of PCR products or amplicon sequencing, allows confident detection of 
differences in specific regions of the genome. Therefore, the percentage of positive gene-
Figure	5-11:	PCR	product	of	RAC2	amplification	
Electroporated	 cells	 (ACT	 1	 CR,	 ACT	 1R)	 and	
untreated	controls	(ACT	1	iPSC)	were	tested	for	RAC2	





edited cell clones can be predicted and the number of clones calculated for analysis. 
Six days after electroporation, the electroporated cells were detached, pooled, and counted 
(Figure 5-9). 6600 cells were used for singularization. The rest were divided into two halves: 
one portion was frozen for future culturing and the other part was harvested to test if the 
HDR emplate was introduced. To this end, genomic DNA was isolated and forward and 
reverse primers for RAC2 were used to amplify the region of interest with PCR. Five µl of the 
PCR product were loaded and run on an 1.5% agarose gel to confirm the correct size of the 
product and specificity of the primers (Figure 5-11). Bands for Rac2 ran at the expected 
height of 299 bp and no nonspecific bands were visible, indicating high primer specificity 
(Figure 5-11). Subsequently, 500 ng of PCR product were used for amplicon sequencing, 
which was carried out by GENEWIZ (South Plainfield, NJ, USA). 
Table	5-2:	Amplicon	sequencing	results	from	batches	of	iPSCs	after	CRISPR/Cas9	editing.	
Batch SNP Total 
Reads 


















20 µM HDR 
enhancer 





30 µM HDR 
enhancer 





The results of the amplicon sequencing indicated the percentage of alleles that contain the 
desired HDR template (Table 5-2). Furthermore, Table 5-2 contains the total sequencing 
reads per sample (total reads), the number of detected insertions in the target sequence, and 
the number of deletions in the sequence. The sample without HDR enhancer had the 
greatest number of reads (57,050), followed by the lower HDR enhancer concentration 
(56,321) and the higher HDR enhancer concentration (52,624). Most insertions were 
detected in the no-HDR-enhancer sample (3875), followed again by the samples with low 
(3105) and high (2616) HDR enhancer concentration. The trend continues when looking at 
deletions: Deletions were detected roughly twice as often as insertions, with the greatest 
number in the sample without enhancer (6817), followed by 20 µM HDR enhancer (6370), 




(no enhancer) to 36.3% (30 µM HDR enhancer) with increasing HDR enhancer 
concentrations. More importantly, the HDR template frequency increased with HDR 
enhancer from 6.6% without enhancer to 10.0% with 30 µM HDR enhancer. There was only 
a small difference in the occurrence of HDR frequencies between 20 µM HDR enhancer 
(9.1%) and 30 µM HDR enhancer (10.0%). These values gave a rough estimate of how 
many single iPSC colonies needed to be picked, cultured, harvested and analyzed in order to 
find the desired quantity of correctly edited clones. 
5.3.5. Sanger sequencing of individual clones 
While amplicon sequencing was carried out, 48 clones were picked from the ACT 1.10_R cell 
line. Each clone was transferred into one well of a 12-well plate and cultured until confluent 
enough for passage into one well of a 6-well plate. Once the clones in the 6-well plate 
reached confluency, the cells were harvested, snap frozen in liquid nitrogen, and stored at -
80°C. The results from amplicon sequencing allowed us to estimate the success rate of gene 
editing. To precisely determine the actual number of homozygously and heterozygously 
edited clones, Sanger sequencing of individual clones was performed. Genomic DNA was 
isolated, Rac2 was amplified with specific primers, and PCR products were sent for Sanger 










Sanger sequencing results were lined up and visualized with the BioEdit software (Figure	
5-12). The software automatically evaluated what kinds of edits occurred (Table 5-3). The 
results showed that regardless of HDR enhancer treatment, heterozygous edits were more 
common than homozygous edits. While heterozygous edits were much more frequent in 
iPSCs treated with HDR enhancer (56.25%), homozygous edits seemed to be more frequent 
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Upon closer assessment of the sequencing peaks, it became apparent that some 
sequencing results were inconclusive and needed more detailed investigation 
(‘uninformative’). This could be due to a “messy” genotype after editing or there might be 
clones with a mixed allele type. Reviewing every sequencing plot individually painted a 
different picture than the initial results (Table 5-4). The number of edited clones per approach 
stayed the same. However, the rate of uninformative results was much higher in samples 
with HDR enhancer (37.5% in both cases) compared to non-treated (6.25%). CRISPR/Cas9 
editing without subsequent HDR enhancer treatment resulted in one clone with a 
homozygous edit and four clones with heterozygous edits. The batch treated with 20 µM 
HDR enhancer resulting also in one clone with a homozygous edit and only in three clones 
with heterozygous edits. Clones from the batch with 30 µM HDR enhancer performed the 










































Successfully edited iPSC lines are currently cultured and tested for stable gene editing with 
Sanger sequencing (Figure 5-13). To confirm heterozygous and homozygous iPSC lines, 
singularization steps will follow. A conclusion about the use of the HDR enhancer can only be 






The	 sequence	 on	 the	 left	 was	 the	 iPSC	 line	 ACT	 1	 R1.26	 that	 was	 edited	 at	 the	 site	 of	 the	 SNP	
rs13058338.	The	edit	resulted	in	the	genotype	AT	at	the	site	of	the	SNP	(left).	In	ACT	1	R1.32,	the	edit	
resulted	in	a	homozygous	edit	(TT)	at	the	relevant	location	(right).	
5.4. Telomere length and elongation 
Telomeres are repetitive DNA sequences at the end of chromosomes that cap and shield the 
chromosomes from damage and fusion (Blasco, 2005). Telomeres shorten with every cell 
division and decrease over our lifetimes because the telomerase enzyme complex, which 
can elongate telomeres, is silenced in the majority of cell types at birth (Blasco, 2005). 
Activation of TERT, the catalytic subunit of the telomerase enzyme complex, in adults 
supports cancer cell survival and drives cancer progression (Liu, 1999; Ducrest et al., 2002). 
Hence, most telomere research has been related to cancer or aging (Hanahan and 
Weinberg, 2000; López-Otín et al., 2013). With the finding that telomerase activity is linked to 
mtDNA protection (Haendeler et al., 2009), and that TERT overexpression reduces 
endogenous ROS production (Indran et al., 2011), telomerase research became highly 
relevant for the field of anthracycline-induced cardiotoxicity. Furthermore, it was reported that 
telomerase activation increased cellular lifespan by restoring telomeres that were shortened 
by oxidative stress (von Zglinicki, 2002, 2006). More recently, it was shown that 
cardiomyocyte-specific telomere shortening plays a role in age-associated and genetic forms 
of DCM (Chang et al., 2016; Chang and Blau, 2018). Furthermore, telomerase activation has 
protective effects in mice after MI (Bär et al., 2014). In addition, telomerase has anti-
apoptotic characteristics in CM (Oh and Schneider, 2002). Telomerase activity is not only 
interesting when looking at CM. In stem cells, telomere stability is maintained through 
balancing elongation and trimming (Flores et al., 2005; Sharpless and DePinho, 2007). 
5.4.1. Telomere length 
Our collaborators, Prof. Thum and Dr. Bähr at the Medizinische Hochschule Hannover, 
previously detected telomere shortening in mice after DOX treatment (Bär et al., 2014; Bär 
and Thum, 2017). With regard to ACT modeling in iPSC-CMs, we wanted to address two 
questions:  




2) Does telomere length differ between iPSC-CMs from control patients compared to 
iPSC-CMs from ACT patients? 
To determine telomere length in iPSCs and iPSC-CMs, we prepared samples for PCR and 
qFISH, and sent them to Hanover for analysis, where PhD candidate Shambhabi Chatterjee 




patients	 and	 controls,	 Phoenix	 iPSCs	 and	 iPSC-CMs	were	 included	 as	 an	 internal	 control.	A:	 qPCR	
results	 indicate	 that	 telomeres	 of	 iPSCs	 are	 longer	 than	 telomeres	 of	matched	 iPSC-CMs.	B:	 qFISH	
results	 show	 that	 telomeres	 are	 longer	 in	 iPSCs	 than	 in	 iPSC-CMs..	 AU=Arbitrary	 unit.	A:	 iPSC:	 n	=	
three	samples	from	three	cell	lines	from	two	patients.	iPSC-CMs:	n	=	six	independent	differentiations	
from	 three	 cell	 lines,	 from	 two	patients.	 (Phoenix:	 n=1)	B:	 iPSC:	 n	=	 three	 samples	 from	 three	 cell	
lines	 from	 two	patients.	 iPSC-CMs:	n	=	five	 independent	differentiations	 from	 three	cell	 lines,	 from	
two	 patients.	 Phoenix	 was	 used	 as	 a	 positive	 control.	 Statistical	 analysis	 was	 performed	 with	 an	
unpaired	 t-test.	P	 values	were	 represented	as	 followed:	p	>0.05	=	*;	p	>0.01	=	**.	Horizontal	bars	
indicate	the	mean	+/-	SEM.	
To answer the question whether telomere length changes during cardiac differentiation, we 
analyzed telomere lengths in iPSCs and iPSC-CMs from ACT patient and control cell lines 
via quantitative PCR (qPCR) and qFISH. The analysis of telomeric repeats via qPCR showed 
that the relative length of telomeres is 50% longer in iPSCs than in iPSC-CMs (Figure	5-14A). 
An additional way to determine telomere length is with qFISH. With this approach iPSC 
telomeres were 1.3-fold longer than iPSC-CM telomeres (Figure 5-14B). Hence, the qFISH 






Telomere	analysis	of	 iPSC-CMs	 indicated	 that	 telomeres	were	shorter	 in	ACT	patients	compared	 to	
control	patients.	n=	three	independent	differentiation	experiments	of	one	cell	line	from	one	ACT	and	
control	patient,	respectively.	AU=arbitrary	units.	Statistical	analysis	was	performed	with	an	unpaired	
t-test.	 Horizontal	 bars	 indicate	 the	 mean	 +/-	 SEM.	 HUVEC	 cells	 were	 used	 as	 marker	 for	 short	
telomeres	in	comparison	to	Phoenix-iPSCs	with	longer	telomeres.		
In the next set of experiments, we compared explicitly the telomere length in iPSC-CMs from 
ACT patients with controls. We found that the relative length of telomeres was shorter in 
ACT-iPSC-CMs compared to control-iPSC-CMs (Figure 5-15). 
This initial set of experiments showed that there are differences in telomere length between 
iPSCs and iPSC-CMs. Furthermore, iPSC-CMs from ACT patients were found to have 
shorter telomeres compared to control patients. Clearly, these preliminary data sets need to 
be supported by additional observations. So far, there is an indication that telomeres are 
shorter in iPSC-CMs from ACT patients compared to control patients. 
5.4.2. Optimization of AAV6-DOX-apoptosis assay 
Telomerase activity in adult cardiomyocytes is thought to be advantageous against 
senescence and aging. A decline in telomerase activity in adult rat hearts through aging has 
been described (Leri et al., 2000). TERT expression and telomerase activity are down-
regulated in the adult rat heart (Oh and Schneider, 2002). Longer telomeres are thought to 
render cells more resistant to DOX-related cytotoxicity (Bär et al., 2014; Beyer et al., 2016; 
Quryshi et al., 2018). Our approach to achieve longer telomeres was to transduce iPSC-CMs 
with AAV6 vectors overexpressing telomerase regulated by a CMV promoter. To determine 
the optimal MOI, iPSC-CMs were transduced with AAV6-green fluorescent protein (GFP) 
vectors, which allowed for a simple read-out of transduction rate. We tested MOIs of 1 x 103, 
5 x 103, and 1 x 104. 
Transduced iPSC-CMs were monitored with a fluorescent microscope. The first green 
fluorescent iPSC-CMs were visible after 24 h in wells that were infected with MOIs of 5 x 103 




AAV6-GFP-infected wells. The highest number of fluorescent iPSC-CMs was detected six 








cytometry.	 For	 each	 plot	 10,000	 iPSC-CMs	 were	 measured.	 Untreated	 iPSC-CMs	 were	 used	 to	
determine	the	baseline	(left).	Increasing	MOIs	resulted	in	increased	percentages	of	GFP-positive	cells.	





A more detailed measure of GFP-positive iPSC-CMs was achieved with flow cytometry. On 
day six, iPSC-CMs were detached and analyzed for GFP expression. Using an MOI of 1 x 
103, the transduction rate was 77%. An MOI of 5 x 103 resulted in 95% GFP-positive cells six 
days after transduction (Figure 5-16B). Doubling the MOI to 1 x 104 increased the 
transduction rate only to 97% GFP-positive cells. Therefore, we determined 5 x 103 as our 
MOI of choice and used it for the following AAV6-tert experiments. 
We hypothesized that iPSC-CMs with enhanced telomerase activity would be more resistant 
to DOX treatment than iPSC-CMs with low telomerase activity. Initial transductions showed 
that AAV6 infection alone caused cell stress, which manifested in detached iPSC-CMs and 
debris in the culture medium (Figure 5-17). These indicators for cellular stress were observed 
with bright field microscopy in iPSC-CMs that were infected either with AAV6 GFP or AAV6 
TERT (Figure 5-17 center and right). Four days after transduction, iPSC-CMs that were 
infected with AAV6 TERT showed decreased cell density (Figure 5-17), indicating cell death. 
Hence, AAV6 transduction might increase apoptosis levels at baseline. To test for increased 
resistance to DOX treatment, we looked at apoptosis rates with the Annexin V apoptosis kit 
for flow cytometry. To avoid increasing stress through DOX treatment and AAV6 
transduction, DOX treatment was initiated 48 h after AAV6 transduction. iPSC-CMs were 
treated with 0.25 µM DOX or 1 µM DOX for 72 h, and the apoptosis assay was carried out on 




AAV6-transduced	 iPSC-CMs	 were	 compared	 to	 uninfected	 controls.	 AAV6	 transduction	 itself	





Bright field microscopy images of iPSC-CMs, which were transduced with AAV6 for 48 h 
followed by DOX treatment for 72 h showed detached iPSC-CMs and a decrease in growth 







CMs.	 iPSC-CMs	 were	 infected	 with	 AAV6	 vectors	 and	 treated	 with	 0.25	µM	 DOX	 and	 1	µM	 DOX,	
respectively.	 AAV6-transduced-	 and	 DOX-treated	 iPSC-CMs	 were	 more	 often	 detached	 from	 the	
culture	plate	 than	untreated	 iPSC-CMs.	Scale	bars	=	20	µM.	C:	Representative	scatter	plots	of	 flow	
cytometry	with	Annexin	V/PI	apoptosis	kit	showed	a	shift	in	cell	distribution	after	DOX	treatment.	D:	
Summary	 of	 flow	 cytometrical	 results.	 AAV6	 vector	 transduction	 increased	 the	 percentage	 of	
apoptotic	and	necrotic	iPSC-CMs.	Treatment	with	DOX	increased	the	apoptosis	rate	further.	n	=	one	
differentiation	of	the	ACT	3.11	iPSC	line.	
AAV6 transduction alone, regardless of AAV6 GFP or AAV6 TERT, was sufficient to result in 
detached iPSC-CMs (Figure 5-18B, top row). Additional DOX treatment increased the 
appearance of detached iPSC-CMs and 1 µM DOX had a greater impact than 0.25 µM DOX 
(Figure 5-18B). Apoptosis assays with flow cytometry confirmed the initial observation. 
Representative scatter blots show that AAV6 GFP-transduced iPSC-CMs were 48% 
apoptotic and necrotic (Figure 5-18C). With DOX treatment, this rate increased to 43% 
(0.25 µM DOX) and 47% (1 µM DOX). iPSC-CMs that were transduced with AAV6 TERT had 
similar apoptosis and necrotic rates with 56% (no DOX), 50% (0.25 µM DOX), and 55% 
(1 µM DOX). With both AAV6 vectors the apoptosis and necrosis rate was higher with 
0.25 µM DOX treatment compared to 1 µM DOX treatment (Figure 5-18C). Due to the high 
stress in iPSC-CMs treated with 1 µM DOX, iPSC-CMs might go into apoptosis or necrosis 
earlier, and cannot be detected by the flow cytometry assay at day five. The reduced iPSC-
CM density on the bright field images supported that explanation (Figure 5-18B). Compared 
to untreated iPSC-CMs, AAV6-transduced iPSC-CMs had a two to three times higher 
apoptosis rate (Figure 5-18D). Contrary to our expectations, DOX increased the apoptosis 
and necrosis rates less than AAV6 transduction. 1 µM DOX treatment accounted for an 
increase of apoptosis and necrosis of eight (GFP) and four percentage points, respectively 
(Figure 5-18D). 
To limit the stress on the iPSC-CMs and to allow for a longer recovery time, the treatment 
protocol was adjusted and DOX treatment was started seven days after the end of the AAV6 
transduction (Figure 5-19A). Furthermore, DOX concentration was set to 0.5 µM, which was 
more tolerable to the iPSC-CMs than 1 µM DOX. These adjustments should not negatively 
influence TERT expression, because it is stable for up to 14 days after transduction (Dr. 
Christian Bär, personal communication). 
5.4.3. AAV6 TERT apoptosis assay 
With the previously mentioned improvements, the flow cytometry apoptosis assay was 
repeated. Representative scatter plots showed that iPSC-CMs without DOX treatment had 
relatively low apoptosis and necrosis rates (Figure 5-19B). For AAV6-untransduced iPSC-
CMs and AAV6 GFP-transduced iPSC-CMs, the rate of non-apoptotic iPSC-CMs was 
approximately 75%. AAV6 TERT-treated iPSC-CMs had a slightly lower non-apoptotic rate 




identical between empty AAV6, and AAV6-untransduced groups (11%-15%), apoptosis rates 
were slightly elevated with AAV6-TERT transduction alone (18%; Figure 5-19C). Treatment 
with 0.5 µM DOX led to an increase in apoptosis rates in all AAV6 conditions (Figure 5-19C). 
In AAV6-untransduced iPSC-CMs the DOX-induced increase of apoptosis rate was 2.8- and 
1.8-fold in ACT- and control iPSC-CMs, respectively (Figure 5-19D). In empty AAV6-
transduced iPSC-CMs, the increase after DOX treatment was the lowest with 1.8-fold in 
ACT-iPSC-CMs and 1.5-fold in control iPSC-CMs. TERT-transduced iPSC-CMs showed an 
increase of DOX-induced apoptosis of 2-fold and 1.5-fold for ACT and control iPSC-CMs, 
respectively (Figure 5-19D). 
Overall, AAV6-TERT transduction did not lead to a significant decrease of apoptosis and 
necrosis rates. Notably, there was a non-significant trend that DOX-induced apoptosis and 
necrosis rates increased more in ACT-iPSC-CMs compared to control-iPSC-CMs (Figure 5-
19C, D), which is in line with previous findings of our group (Haupt, 2018). Apoptosis and 
necrosis rates decreased slightly with empty AAV6 transduction compared to AAV6-
untransduced iPSC-CMs after DOX treatment, but no vector rescued the iPSC-CMs from 





Figure	 5-19:	 Flow	 cytometry	 apoptosis	 assay	 of	 iPSC-CMs	 after	 TERT	 overexpression	 and	 DOX	
treatment.	
A:	 Time	 line	of	AAV6	 transduction,	 recovery	period,	 and	DOX	 treatment.	B:	 Representative	 scatter	
plots	 show	 gate	 setting	 for	 cell	 size,	 and	 in	 the	 other	 field	 for	 red	 fluorescence	 (y	 axis)	 and	 blue	
fluorescence	 (x	 axis).	 Scatter	 plots	 show	 distinctly	 different	 cell	 distribution	 depending	 on	 DOX	




top	 right),	 early	 apoptotic	 (Q3-	 bottom	 right),	 and	 non-apoptotic	 iPSC-CMs	 (Q4-	 bottom	 left).	
Numbers	 indicate	 the	 percent	 values	 of	 total	 cell	 count.	 The	 difference	 between	 the	 sum	 of	
percentage	 values	 and	 100%	 is	 the	 number	 of	 counted	 events	 outside	 the	 gated	 population.	 C:	
Quantified	 flow	 cytometry	 data	 show	 that	 DOX	 treatment	 increased	 the	 mean	 percentage	 of	
apoptotic	and	necrotic	iPSC-CMs	in	each	group.	D:	Fold-change	data	indicates	a	significant	increase	in	
apoptotic	 iPSC-CMs	 after	 DOX	 treatment	 in	 the	 ACT	 patient	 group	without	 vector	 treatment.	 The	
increase	 of	 DOX-induced	 apoptosis	 rate	 did	 not	 change	 significantly	 with	 vector	 treatment.	 AU=	
arbitrary	unit.	n	=	one	independent	iPSC-CM	differentiation.	ACT	patient	and	control	patient:	n=	two	
to	 four	 differentiations	 from	 one	 iPSC	 line	 from	 one	 patient,	 respectively.	 Statistical	 analysis	 was	
performed	with	two-way	ANOVA.	Horizontal	bars	indicate	the	mean	+/-	SEM.	
5.4.4. AAV6 TERT ROS assay 
Apoptosis can be triggered through different pathways and cells have a plethora of 
compensational mechanisms in place, so not every form of distress leads to self-destruction. 
Therefore, the measurement of the apoptosis rate has limitations when assessing the effects 
of DOX treatment. A more direct effect of DOX is the increase in ROS, which can be 
measured with the Amplex red assay (Zhou et al., 1997). iPSC-CMs were transduced with 
AAV6 vectors and challenged with 0.5 µM DOX for 72 h, as described before. Subsequently, 
the iPSC-CMs were incubated with an Amplex red probe and luminescence was measured 






ROS	production	of	 iPSC-CMs	was	 indicated	 through	Amplex	 red	 luminescence.	 iPSC-CMs	 from	ACT	
patient	 3	 were	 infected	 with	 AAV6	 vectors	 and	 treated	 with	 0.5	µM	 DOX.	 Uninfected	 iPSC-CMs	
served	 as	 reference.	A:	 DOX-treated	 iPSC-CMs	 produced	more	 ROS	 than	 untreated	 cells.	 This	was	
consistent	throughout	the	groups.	B:	When	luminescence	values	were	normalized	to	respective	DOX-






In all groups, there was a significant increase in ROS after DOX treatment. AAV6 TERT-
transduced iPSC-CMs produced more ROS at baseline compared to untreated cells and 
empty vector-treated iPSC-CMs (Figure 5-20A). The luminescence values after DOX 
treatment did not differ significantly between the groups. When normalized to respective 
untreated values, the fold-change increase in ROS after DOX treatment was slightly lower in 




AAV6 TERT (Figure 5-20B). Overall, the results of the Amplex red assay were comparable to 
the outcome of the apoptosis assay.  
5.5. Characterization of the DCM cohort 
ACT can be described as an induced form of DCM. To assess if some of the investigated 
disease mechanisms are specific to ACT, or if they are general heart failure symptoms, we 
added iPSC-CMs from DCM patients to the project. 
One patient diagnosed with DCM end stage heart failure followed by heart transplantation 
and one healthy control donor were willing to donate somatic material for iPSC generation. 
We established and characterized iPSCs and iPSC-CMs from these individuals and included 
them in this study as a reference for heart failure without anthracycline induction. This helped 
to differentiate between ACT-specific disease mechanisms and general heart failure 
processes. 
5.5.1. iPSC characterization 
Reprogramming for all somatic cells of the different donors was performed in former studies 
of the group with the non-integrative Sendai virus (Table 3-1). Characterization of newly 
generated cells is crucial because iPSCs that have undergone only partial reprogramming 
might not be capable of differentiation into iPSC-CMs sufficiently (Koyanagi-Aoi et al., 2013; 
reviewed by Takahashi and Yamanaka, 2016). To confirm stemness and pluripotency, two 
cell lines per donor were selected and tested for stem cell-like morphology and expression of 














5.5.1.1. Morphology, alkaline phosphatase expression, 
    and pluripotency markers 
Stem cells have a characteristic morphology, as they are relatively small, round, and form 
colonies that have a clear boundary towards the rest of the plate. Investigated iPSCs from 
the DCM patient and the Crt-DCM donor showed typical morphology as described for human 
pluripotent stem cells and showed high alkaline phosphatase activity (Figure 5-21, top left 
panels). Presence of pluripotency proteins was investigated with immunofluorescence 
analysis. The acquired images revealed that the investigated cells were positive for 
pluripotency markers. Staining of transcription factors like homeobox protein NANOG 
(NANOG), Oct-4, and SOX2 resulted in nuclear signals. Immunopositive signals from the 
keratin sulfate antigen TRA-1-60 and stage-specific embryonic antigen 4 (SSEA-4) were 
seen in the cell membrane. The RNA-binding protein Lin-28 homolog A (LIN28; encoded by 
LIN28) (Tsialikas and Romer-Seibert, 2015) was located in the cytoplasm (Figure 5-21). To 
test the abundance of mRNA of pluripotency markers in the cells, we performed 
semiquantitative RT-PCR with primers for SOX2, Oct-4, NANOG, and LIN28. Equal loading 
was controlled through the housekeeping genes HPRT (for Crt-DCM 2.1 and 2.2) or GAPDH 
(for DCM 1.6 and DCM 1.10). All investigated pluripotency genes were up-regulated and 
highly expressed in the iPSC lines compared to the parental somatic cells (PBMCs from Crt-









5.5.1.2. Spontaneous differentiation potential in vitro 
The characterization of newly generated iPSCs included their capacity for spontaneous 




spontaneous differentiation in the iPSCs by using the EB methodology and the expression of 
specific markers for each germ layer. iPSCs of passages no higher than twelve were cultured 
together with MEFs in suspension for eight days to allow for the development of round EBs. 
At day eight, EBs were plated on gelatin-coated plates and cultured for an additional 25 
days. During this time, cells grow out of the EBs while differentiating into all three germ 
layers. At days 0, 8, and 8 + 25, samples were taken, RNA was isolated and differentiated 
cells were tested for expression of genes characteristic of all three germ layers with 
semiquantitative RT-PCR (Figure 5-23). MEFs were used as negative control.  
	
Figure	 5-23:	 PCR	 results	 show	 expression	 of	 germ	 layer	marker	 genes	 at	 three	 time	 points	 during	
spontaneous	differentiation.	
MEFs	served	as	negative	control.	MEF	=	mouse	embryonic	fibroblasts.	
RT-PCR results showed a decline in the expression of the stem cell marker Oct-4 in a time 
dependent manner in both cell lines tested (Crt-DCM 2.1 and Crt-DCM 2.2) with a remaining 
Oct-4 expression at time point 8 + 25 in Crt-DCM 2.1 (Figure 5-23) suggesting a few cells 
were undifferentiated at that time point. Furthermore, in all cell lines the expression of 
endodermal markers, AFP, ALB, and a mesodermal marker, cTnT, increased with 
differentiation time. The ectodermal marker tyrosine hydroxylase (TH) was already 
expressed in undifferentiated cells, which was unexpected. This signal might have come 
from cells that had spontaneously differentiated during stem cell culture. The clear 
expression of TH at day 8 + 25 was according to our expectations. The expressions of these 





Taken together, the cells derived from PBMCs of Crt-DCM or skin fibroblasts of DCM patient 
had a stem cell-like morphology, expressed characteristic stem cell markers on mRNA and 
protein level, and were capable of differentiating into all three germ layers, which leads to the 
conclusion that these cells are induced for pluripotency. 
5.5.2. Generation and characterization of iPSC-derived cardiomyocytes  
To obtain a high number of pure cardiomyocytes, Crt-DCM and DCM-iPSCs were 
differentiated in cardiomyocytes as described before. iPSC-CMs were cultured for at least 60 
days after onset of differentiation before they were used for experiments. Ten to 14 days 
after initiation of differentiation, the distinctive characteristic of contraction could be observed 
for the first time. To confirm the manifestation of cardiomyocyte cell structure, iPSC-CMs 
were stained for alpha-actinin (Figure 5-23 A, B) using immunocytochemistry. The 60-day-old 
Crt-DCM and DCM-iPSC-CMs had a heterogenous morphology from round to long-shaped 
cells (Figure 5-24). Alpha-actinin staining of Crt-DCM-iPSC-CMs showed a highly organized 
sarcomeric structure with clear striations. We observed also bi- and multinucleated cells in 






5.5.2.1. Cell size measurement 
DCM and hypertrophic cardiomyopathy (HCM) often occur in a mixed form. To determine if 
the generated DCM 1 iPSC-CMs differ in volume and size from control cells, we measured 
the cells with CASY Cell Counter & Analyzer (OLS OMNI Life Science, Bremen, Germany). 
To gain a broader understanding of the relation of cell size, an additional iPSC line from a 
second DCM patient was added to the analysis (DCM 3). The DCM 3-iPSCs were 




Representative brightfield images of CRT 1-, DCM 1-, and DCM 3-iPSC-CMs showed that 
iPSC-CMs of the DCM 1 line were smaller compared to the other iPSC-CMs (Figure 5-25A). 
Results of the volume- and diameter measurements confirmed that iPSC-CMs of the DCM 1 
patient were significantly smaller than iPSC-CMs from the control cell line (Figure 5-25B). 
DCM 3-iPSC-CMs were significantly larger than control and DCM 1-iPSC-CMs. The 
differences were consistent between volume measurement and diameter measurement 
(Figure 5-25B).  
iPSC-CMs from DCM 1 patient 1 were significantly smaller than controls and cells of DCM 





patient	 3	 (DCM	3)	 differed	 significantly	 in	 cell	 volume	 from	 control-iPSC-CMs	 (CRT	1).	 DCM	1	 cells	
were	significantly	smaller	than	CTR	1	cells	and	DCM	3	iPSC-CMs	were	significantly	 larger.	The	three	
tested	 cell	 lines	 differed	 significantly	 in	 cell	 diameter.	 n	 =	 average	 cell	 volume/diameter	 of	
approximately	 6000	measured	 cells	 from	 one	 well	 of	 a	 12-well	 plate.	 CTR	 1:	 Two	 differentiations	






5.5.2.2. Regularity of sarcomeric structure 
A previous study from our group investigated the impact of DOX on the sarcomeric regularity 
of iPSC-CMs from ACT patients, which were also used for this study (Haupt, 2018). It was 
shown that sarcomeric regularity in ACT-iPSC-CMs after DOX treatment is reduced and that 
the reduction is greater in ACT-iPSC-CMs compared to control iPSC-CMs (Haupt, 2018). 
While ACT and DCM patients shared a common disease phenotype, the main difference 
between these cardiomyopathies is the trigger of the disease. Therefore, we were interested 
if effects of DOX on the sarcomere are universal in diseased iPSC-CMs or if the susceptibility 
is specific to ACT-iPSC-CMs. 
Sarcomeres are the smallest functional units of myofibrils. Lesions in these units can have 
detrimental effects on force development and contractile function (Eschenhagen et al., 2015). 
In this study, we wanted to investigate whether the previously described reduction in 
sarcomeric regularity after DOX treatment can also be observed in end-stage heart failure 
DCM-iPSC-CMs. In this way we can test whether this phenomenon is common in heart 
failure, specific to DOX-predisposed patients or based on certain genetic backgrounds. To 
assess sarcomeric integrity, we tested the regularity of sarcomeres in our iPSC-CMs with 
immunocytochemistry. Application of FFTA on the microscopy images allowed for a 
qualitative assessment of regularity of the observed structures and therefore for an objective 





Figure	 5-26:	 Representative	 α-actinin	 immunofluorescence	 images	 of	 DOX-treated	 iPSC-CMs	 and	
untreated	iPSC-CMs.	
Cells	were	stained	for	alpha-actinin	and/or	titin.	Scale	bars	=	100	µm.	
Representative images demonstrated regular alpha-actinin structures in untreated Crt-DCM 
cells, whereas the sarcomeric regularity is impaired upon DOX treatment at low and high 
concentrations as seen in the α-actinin staining (Figure 5-26 upper panel). In DCM 1- and 
DCM 3-iPSC-CMs, regularity of sarcomeric structures was already impaired without DOX 
treatment (Figure 5-26). In addition, DOX treatment worsened the impairment in sarcomeric 
structures of the cells. 
Quantification of sarcomeric regularity confirmed the trend seen in the immunofluorescent 
images, namely that DOX treatment was detrimental to sarcomeric regularity (Figure 5-27A). 
The DOX-induced decrease in sarcomeric regularity was most prominent in Crt-DCM cells 
and less clear in iPSC-CMs from DCM 1 and DCM 3 (Figure 5-27A, B). This is in line with the 
observed reduction in sarcomeric regularity of ACT-iPSC-CMs after DOX treatment (Haupt, 
2018). Among all three tested conditions, Crt-DCM-iPSC-CMs showed significantly higher 
sarcomeric regularity than iPSC-CMs from DCM 1 and DCM 3 (Figure 5-27C). DOX 
treatment had detrimental effects on sarcomeric regularity in healthy and diseased iPSC-
CMs. When sarcomeres were intact as in the Crt-iPSC-CMs, the observed DOX effect was 




low structural regularity under untreated conditions, and therefore the effect through DOX 
treatment was small. 
Analysis of sarcomeric regularity in the iPSC-CMs from DCM patients showed that treatment 
for 24 h with 1 µM DOX leads to more irregular sarcomeric structure in iPSC-CMs from Crt-
DCM, DCM 1, and DCM 3. The most significant decrease of sarcomeric regularity after DOX 
treatment was detected in Crt-DCM-iPSC-CMs. In iPSC-CMs of DCM 1 and DCM 3, the 
observed decrease of sarcomeric regularity after DOX treatment was minimal, likely due to 






A:	 Sarcomeric	 regularity	 in	 iPSC-CMs	 from	Crt-DCM	2,	DCM	1	 and	DCM	3.	DOX	 treatment	 reduced	
the	sarcomeric	regularity	in	all	cell	 lines.	B:	DOX-induced	relative	change	in	sarcomeric	regularity	of	






=	 calculated	 regularity	 from	one	microscopy	 image.	 Crt-DCM	2:	n	 =	28-33	 images	of	 cell	 from	one	
differentiation.	DCM	1	and	DCM	3:	n	=	61-68	 images	 from	three	 independent	differentiations	 from	




6.1. Uptake, retention, and distribution of DOX in iPSC-CMs 
Accumulative doses of DOX are the most reliable predictor of ACT development (Lefrak et 
al., 1973; von Hoff et al., 1979; Swain et al., 1997; Lotrionte et al., 2013; Ewer and Ewer, 
2015). Although DOX has been long known to cause cardiac myopathies, the exact 
mechanisms have not been unraveled (Tripaydonis et al., 2019). DOX was shown to bind to 
mitochondrial cardiolipin extracted from rats in an experimental set-up with cardiolipin-
containing monolayers (Goormaghtigh et al., 1990). Binding of DOX and its subsequent 
reduction to a semiquinone damages the mitochondrial membrane (Mordente et al., 2001). 
This damage interrupts the electron transport chain and lets electrons leak out into the 
cytoplasm, causing elevated levels of ROS (Mordente et al., 2001). This effect was shown in 
rabbit, rat, mouse, pig, monkey, and dog models (Herman and Ferrans, 1997; Robert, 2007; 
Lamberti et al., 2014). Furthermore, DOX-induced damage was reported in human cells in 
vitro, with a greater effect in relatively mature iPSC-CMs of 60 days compared to 30-day-old 
iPSC-CMs (Cui et al., 2019). Studies in mouse and rat models revealed that activation of 
autophagy and mitophagy following DOX treatment protects from cardiotoxicity (Mitra et al., 
2007; Kawaguchi et al., 2012; Hoshino et al., 2013; Xu et al., 2013; Dutta et al., 2014). 
Hence, dysregulation of endogenous autophagy and mitophagy through DOX are likely to 
contribute to cardiotoxicity (recently reviewed by Koleini and Kardami, 2017). Furthermore, 
DOX increases cellular ROS levels by so-called redox cycling (Davies and Doroshow, 1986). 
DOX is also known to induce DNA double-strand breaks, damaging cellular and mtDNA. A 
study that used 8-hydroxydeoxyguanosine as a biomarker for DNA damage in rats reported 
that mtDNA in the heart was affected more by DOX than mtDNA in the liver. Furthermore, 
mtDNA damage in the heart was twice as severe as nuclear DNA damage in the heart 
(Serrano et al., 1999). This effect was also prominent in a mouse model (Adachi et al., 1993), 
and was reported in a model of long-term cardiotoxicity (Hixon et al., 1981). Mitochondria 
with faulty DNA cannot replicate efficiently. Therefore, mtDNA damage is thought to 
contribute mainly to the development of late-onset, chronic cardiotoxicity (Wallace, 2003; 
Lebrecht and Walker, 2007).  
Until now it has not been clearly determined how DOX increases ROS, where in the cell it 
binds, how it triggers long-term toxicity, and where in the cell most DOX accumulates. With 




prevent ACT, without hampering its anti-neoplastic properties. So far, there has not been a 
study that methodically quantified intracellular DOX levels in human cardiomyocytes. In this 
study, we used HPLC to analyze the amounts of DOX in iPSC-CMs of ACT patients and 
control patients after DOX treatment. We varied DOX concentrations, treatment times, and 
recovery periods and found that intracellular DOX levels positively correlate with DOX 
concentration and with treatment time. Furthermore, these data show that intracellular DOX 
levels decrease significantly after a recovery period of three days in control iPSC-CMs and 
seven days in ACT-iPSC-CMs. 
Initially, it was important to establish the HPLC DOX detection approach for biological 
samples such as iPSC-CMs. We used an adaption of a previously described protocol to 
measure DHE for ROS analysis (Fernandes et al., 2007). HPLC had been used formerly to 
determine DOX levels in aqueous solutions (Wood et al., 1990), rat serum, and homogenized 
lung tissue from pigs (Kümmerle et al., 2003).  
Our data show a correlation between the concentration of DOX treatment and intracellular 
DOX levels. In the tested range up to 5 µM DOX, iPSC-CMs did not saturate with DOX. In 
ACT-iPSC-CMs, intracellular DOX levels were twice as high in samples treated with 1 µM 
DOX compared to 0.5 µM DOX. Five times higher DOX concentrations (from 1 µM to 5 µM) 
also resulted in a five-fold increase of intracellular DOX (Figure 5-1A). In a limited number of 
differentiation experiments, we found higher absolute DOX levels in ACT patient iPSC-CMs 
compared to control under nearly all conditions (Figure 5-1). This finding requires 
confirmation using data from more independent differentiation experiments. 
It was reported over 40 years ago that DOX enters Ehrlich ascites tumor cells via diffusion 
(Skovsgaard, 1977). For the lipophilic DOX molecules, cell membranes do not constitute a 
hurdle (Tripaydonis et al., 2019). In line with these previous findings, there seems to be little 
regulation by the cell membrane on how much DOX enters iPSC-CMs. In the present study, 
it was shown that in both the ACT patient and control patient groups, DOX levels in samples 
treated with 5 µM DOX were about five times higher than in samples treated with 1 µM DOX 
(Figure 5-1). Therefore, potentially saturating DOX concentrations have to be higher than 5 
µM. In cancer patients, DOX concentrations in blood plasma only exceed 5 µM for few 
minutes right after DOX infusion (Greene et al., 1983). If recommendations regarding 
prolonged infusion of DOX with reduced flow are being followed, saturation might not be 
reached in clinical settings (Legha et al., 1982; El-Kareh and Secomb, 2000). DOX levels in 
iPSC-CMs from ACT patients tend to be higher than in control patients. If this difference is 
due to increased resorption of DOX in ACT patients compared to control patients or if it is 
due to a difference in efflux efficacy between the two groups remains undetermined. It is 




exporters are involved. The SNP rs8187710 in the ATP-binding cassettes subfamily C 
member 2 (ABCC2) is one of only three SNPs that significantly increased the risk of 
cardiotoxicity in patients treated with anthracyclines indicating the possible involvement of 
ABC transporters in ACT. ABCC2 is part of a superfamily of transport proteins that transport 
substrates across the cell membrane in an ATP-dependent manner (Elens et al., 2011). 
Occurrence of the rs8187710 SNP has been shown to reduce ATPase activity and cause a 
reduced efflux activity due to an amino acid change in the mRNA sequence (Elens et al., 
2011). However, no experimental data exist on the prevention of ACT by rs8187710.  
For time course experiments, iPSC-CMs were treated with 1 µM DOX for up to 72 h and 
intracellular DOX values were measured after 0.5, 2, 6, 24, 48, and 72 h without recovery 
time between treatment and harvest. We found that treatment time determines intracellular 
DOX content. Intracellular DOX was already detectable after 0.5 h of treatment and 
continued to increase up to 48 h. In ACT-iPSC-CMs, intracellular DOX levels after 48 h were 
increased 4.5-fold compared to the 0.5 h time point. In the same period, intracellular DOX 
levels of control iPSC-CMs increased 11.6-fold (Figure 5-2A). Levels between 6 h and 24 h 
treatment time only differed slightly in both groups (ACT and control; Figure 5-2). The lower 
values at the 72 h time point can be explained by increased cellular stress and subsequent 
apoptosis. This hypothesis is underlined by our former studies with these cells, where we 
showed that the apoptosis rate after 24 h of 1 µM DOX treatment was around 15% and had 
doubled after 72 h of 1 µM DOX treatment (Haupt, 2018). Also, Burridge and colleagues 
reported an apoptosis rate of 55% in iPSC-CMs that were treated with 1 µM DOX for 72 h 
(Burridge et al., 2016). To compare intracellular DOX levels for treatment times beyond 48 h, 
it would be necessary to normalize the HPLC values to cell numbers at sample harvest. In 
conclusion, our results show that DOX enters iPSC-CMs immediately and that intracellular 
DOX levels increase over time. 
Studies on DOX concentrations in plasma during treatment suggest rapid clearance of the 
drug from the circulation (Greene et al., 1983). It has not been assessed if DOX molecules 
remain in human cardiomyocytes for extended periods after treatment. In our work, we 
treated iPSC-CMs with 1 µM DOX for 24 h and then allowed the cells to recover for 3 and 7 
days. Our results demonstrate that three days after treatment, intracellular DOX levels were 
about 50% lower than immediately after treatment, and after seven days, DOX levels were 
close to the detection limit in both groups (Figure 5-3). Normalized values show that 
intracellular DOX levels were lower in the control patient group after three days and in the 
ACT patient group after seven days. The clearance rate in the iPSC-CMs from ACT patients 




One limitation of the recovery assay is that other sources of DOX degradation cannot be 
excluded. Degradation of DOX in water can be driven by ambient light (Racles et al., 2019). 
Although later studies claim that DOX is photostable, it is accepted that light can trigger 
oxidation- and catalyst-driven breakdown (Wood et al., 1990; Kaushik and Bansal, 2015). 
Therefore, exposure to ambient light was avoided as much as possible. While our samples 
were shielded from light in the incubators, the abundance of oxygen might have reduced 
DOX levels. Furthermore, iPSC-CMs were cultured at 37°C in full cardio culture medium, 
including antioxidants, which could promote DOX degradation. DOX is stable at a pH value 
of 7, with significantly decreasing stability in solutions with higher or lower pH value. We used 
a Tris-based lysis buffer with a pH value of 7.4. Additionally, samples were washed and 
resuspended with PBS, also using a pH of 7.4. During handling, samples were kept on ice, 
covered with tin foil, and when lined up for measurement, HPLC samples were shielded from 
light and cooled to 4°C. These measures were consistently applied to reduce DOX 
breakdown. Hence, HPLC sample preparation from our iPSC-CMs was comparable to the 
described preparation performed by Kümmerle et al. (2003). Normalized recovery data show 
that a significant reduction of intracellular DOX is reached after three days in control iPSC-
CMs, while it takes seven days to reach a significant decrease in ACT-iPSC-CMs (Figure 
5-3B). 
6.2. Intracellular distribution of DOX 
During membrane isolation, we noted that the mito fraction pellet of DOX-treated cells had a 
strong red coloration. Since this coloration was only present in pellets from DOX-treated 
cells, it was likely that it stemmed from the remaining drug, which would be in line with 
findings that DOX binds to mitochondrial cardiolipin (Goormaghtigh et al., 1980; Aryal and 
Rao, 2016). To test this hypothesis with quantifiable data, iPSC-CMs from ACT patients and 
control patients were treated with 1 µM DOX for 24 h and then immediately lysed. The 
lysates were fractionated with differential ultracentrifugation, which resulted in three distinct 
cell fractions: the first fraction with mitochondria and nuclei, a fraction with cellular 
membranes, and the remaining plasma membrane fraction. To produce the fractions, 
centrifugation was preferred over commercial fractionation kits (for example “Subcellular 
Protein Fractionation Kit for Cultured Cells”, Thermo Scientific), because these kits use 
different lysis buffers with different pH. In our approach, the pH was consistent throughout 
the fractions. Acetonitrile was added to the fractions to dissolve DOX before samples were 
prepared for HPLC measurement.  
We found that more than half of the total DOX was detected in the mito fraction in both ACT 
and control. The DOX levels in the mito fractions were significantly higher compared to the 
membrane fractions (Figure 5-4, appendix). The mean DOX amount was insignificantly 




high affinity for mitochondrial cardiolipin (Nicolay et al., 1984; Goormaghtigh et al., 1990; 
Aryal and Rao, 2016), this result was expected. Generally, the pellet size of the mito fraction 
was considerably larger than the one of the membrane fractions. Therefore, protein 
concentrations of the fractions were determined with a Bradford assay and HPLC values 
were normalized to the respective protein concentrations. Comparing normalized values, the 
distribution of DOX did not differ between the three fractions. In the control patient group, the 
mito fraction still had the highest amount of DOX, referred to the total amount in control 
iPSC-CMs. Looking at fractions of total DOX content in the ACT patient group, DOX values 
were higher in the membrane fraction and the cytoplasm compared to the mito fraction. This 
was contrary to our hypothesis, where binding affinity of DOX would suggest that even when 
normalized to protein content, most DOX would be bound to cardiolipin and hence 
associated with the mito fraction. Escribá et al. (1995) reported that Daunorubicin, an 
anthracycline drug like DOX, directly influences levels of membrane-associated G proteins 
and protein kinase C-alpha beta in the heart. This indicates a direct interaction with 
membrane proteins. More recently, it was shown in model membranes that DOX location in 
membranes is mediated by non-covalent interactions such as electrostatic, hydrophobic, and 
van der Waals interactions (Alves et al., 2017). However, the authors did not specify if that 
results in a high or low probability of DOX retention in the membrane. 
Our findings do not contradict previous observations that DOX has a high affinity for 
mitochondria. It could be that when cells are challenged with a relatively high dose of DOX 
as 1 µM, it binds to certain proteins with high affinity, but due to high plasma levels, it also 
binds to other proteins in a nonspecific manner. To test this hypothesis, this experiment 
could be repeated either with lower DOX concentrations or with a recovery period of 24 to 
48 h. Measuring DOX distribution after a short recovery period would provide additional 
information about whether DOX is cleared simultaneously from all cell compartments, or if 
there are cellular areas in which DOX is retained longer than in others. 
Although sample preparation was always done consistently, it should be noted that part of 
the samples were prepared at the University Hospital Göttingen and others at King's College 
London. This circumstance could partially explain the variance of data points in Figure 5-1. 
Another limitation could have been the temporal distance between the measurements 
because HPLC values depend to some extent on the age of the column and the power of the 
laser; both of which change over time. Data points from the subcellular distribution 
experiments (Figure 5-4) were all prepared in one location and measured within a few weeks 
of each other. They show a smaller variance, which is in line with the described limitation. 
Nevertheless, the data in Figure 5-1, Figure 5-2, and Figure 5-3 show a clear trend, which 




Here we show for the first time the resorption of DOX in human iPSC-CMs. These results 
provide evidence that DOX molecules do not remain in cardiac cells for extended periods. 
This implies that long-term cardiotoxicity is driven by impairments that were caused by an 
initial DOX interaction in a hit-and-run manner. 
6.3. DOX-induced translational decrease in iPSC-CMs 
In gene expression experiments with the described ACT- and control iPSC-CMs, many 
genes encoding for proteins that compose sarcomeric structure or calcium homeostasis were 
down-regulated after DOX treatment (Haupt, 2018). To test if this effect would also be seen 
on the translational level, global mRNA translation in iPSC-CMs after DOX treatment was 
tested with the surface sensing of translation (SUnSET) method (Schmidt et al., 2009). This 
approach is nonradioactive, quantifiable, and does not require any pretreatment of the cells. 
In brief, puromycin, a structural analog of aminoacyl transfer RNAs, is integrated into forming 
polypeptide chains, which terminates translation. Blocked ribosomes release puromycin-
marked polypeptide chains, which in turn accumulate and can be detected with a puromycin 
antibody. The amount of puromycin signal correlates directly with global mRNA translation. 
Although this method might have its limitation when used to analyze glucose-starved cells 
during metabolic selection (Marciano et al., 2018), it worked well in the iPSC-CM model with 
full cardio culture medium.  
In this assay, iPSC-CMs were treated with 1 µM DOX for 24 h, which led to a significant 
reduction in mRNA translation. This trend could be detected in all patients and control cell 
lines and was significant in both the ACT patient and the control patient groups. The effect of 
DOX treatment on mRNA translation was comparable in both groups, with a 20% reduction 
after 24 h of 1 µM DOX treatment. Our results are in between previously reported rates, 
where the translation was reduced after 24 h with 1 µM DOX treatment by only 2% in human 
keratinocytes (Sauter et al., 2010) and by 75% in prostate cancer cells (White et al., 2007). 
White et al. (2007) reported that decreased translation was caused by sustained 
phosphorylation of elongation factor 2 (EF-2). Elevated ROS levels trigger kinase-
independent phosphorylation of EF-2, which obstructs protein elongation (White et al., 2007). 
Additionally, in a genome-wide integrative systems biology approach in yeast, it was shown 
that DOX treatment negatively affected several pathways related to ribosome biogenesis and 
mRNA translation (Taymaz-Nikerel et al., 2018). 
Having established that DOX reduces the global mRNA translation rate, we were also 
interested if transcription is decreased globally. Therefore, we performed whole 
transcriptome analysis with next generation sequencing of generated 3D-engineered heart 
muscle (EHM) from ACT and control iPSC-CMs after DOX treatment. We identified 1106 up-




patient and control EHMs after DOX treatment (unpublished data from our group). GO 
enrichment analysis of DOX-induced DEGs in both control and ACT-EHMs identified 
significantly increased expression of genes with key functions including programmed cell 
death (e.g. BCL2L1, FAS, BAX) or regulation of catabolic processes (e.g. STAT3, ABHD5).  
Furthermore, we found significant decreases in the expression of actin cytoskeletal 
organization (e.g. ACTA2, MYBPC3, MYH6, MYH7, MYL2, MYL7, TNNI3, TNNT2), muscle 
contraction (e.g. LDB3, MYBPC3, MYH6, MYL2, MYOM1, SORBS1, STMN1, TCAP, 
TNNT2), and chromosome organization (2.19%, BRCA2, TOP2A, TOP2B) in both groups 
after DOX treatment (data not shown). This shows that while several genes have decreased 
transcription after DOX treatment, other genes are up-regulated, or not changed at all. 
Overall, transcription is changed in a much more differentiated way than mRNA translation. 
Hence, reduced translation after DOX treatment is not a direct result of decreased 
transcription but must have transcription-independent causes. 
mRNA translation initiation is mainly regulated through a conserved mechanism, involving 
the phosphorylation of the initiation factor eIF2α, which is a downstream actor in the 
mechanistic target of rapamycin (mTOR) pathway (Wang and Proud, 2006). This pathway is 
a major regulator in cellular metabolism, growth, maintenance of homeostasis, and 
autophagy (Zhao et al., 2015; Manning and Toker, 2017; Sciarretta et al., 2018a, 2018b). As 
such, it is a highly interesting target to study in ACT because there have been reports about 
ROS regulation through the mTOR pathway. Increased mTOR signaling results in increased 
Nox2 mRNA levels and elevated ROS in endothelial cells (Reho et al., 2019). Also, growth 
factor-induced ROS in T-cells is mediated through mTOR signaling and NOX activity (Silva et 
al., 2011). Inhibition of mTOR signaling through DOX treatment was reported to induce 
cardiac dysfunction through p53 (Zhu et al., 2009).  
To gain a complete understanding of the interplay between DOX damage and mTOR 
signaling, it would be worthwhile to consider another downstream target of mTOR signaling: 
autophagy. Autophagy is a cellular mechanism in which dysfunctional components are 
engulfed, degraded, and recycled. Autophagy and its mitochondrial form, mitophagy, are 
greatly affected by DOX treatment (reviewed by Bartlett et al., 2017). Restoration of 
autophagy by regulating the AMP-activated protein kinase (AMPK)/mTOR pathway had 
ameliorating effects on DOX damage in rat cardiomyocytes and a mouse model (Cao et al., 
2017). Recently, it was shown that ROS-induced autophagy is inhibited through NF-E2-
related factor 2 during extended periods of oxidative stress (Kosztelnik et al., 2019). This 
inhibition is facilitated through delayed down-regulation of AMPK expression. 
Even a few years ago the understanding of autophagy was very limited (reviewed by Shintani 




and pathological processes. Autophagosome flux, or autophagic flux, has been described as 
a quantitative measure of the flow rate of material along the autophagosome pathway (Loos 
et al., 2014; Galluzzi et al., 2017). With the recently developed innovations in the 
quantification of autophagic flux, there will be advances in the characterization of autophagy 
in the development and progression of cardiac diseases (Yoshii and Mizushima, 2017; du 
Toit et al., 2018). Since NADPH oxidases regulate autophagy in cardiomyocytes, our ACT 
model with a distinct RAC2-related genetic background is a promising tool to unravel affected 
pathways in DOX-induced cardiotoxicity (Sciarretta et al., 2015). The findings of Lee et al. 
(2019) underline the importance of Nox2 regulation in cardiac health. They showed that 
exercise can restore auto- and mitophagy and down-regulate NOX2 in mice, and hence has 
a cardioprotective effect even after DOX treatment. It has not been investigated if restoration 
of autophagy is directly mediated through mTOR signaling, and if mRNA translation would be 
rescued as well. Our iPSC-CMs provide a platform to investigate these processes in a 
human model. 
Taken together, our findings on the reduction of mRNA translation through DOX treatment 
and previous reports on DOX effects on oxidative stress, autophagy, and the Akt/mTOR 
pathway suggest that DOX influences fundamental cellular processes. It is still unknown to 
which extent the described changes are causes or consequences of the detrimental effects 
of DOX treatment. This iPSC-CM model is a valuable tool to research the molecular 
mechanisms behind ACT development in human iPSC-CMs with an ACT-specific genomic 
background. 
6.4. Gene editing with CRISPR/Cas9 
Clinical studies have established a linkage between a SNP in the RAC2 gene, which 
encodes for an activator of the Nox2 enzyme complex, and the development of ACT after 
DOX treatment (Wojnowski et al., 2005; Reichwagen et al., 2015). Although the RAC2 SNP 
rs13058338 is located in an intronic region, the occurrence of the SNP has been associated 
with higher mRNA expression of RAC2 and also of the Nox2 subunit p40phox (encoded by 
NCF4) in granulocytes (Schirmer et al., 2008). Increased activity of Rac2 would result in 
elevated superoxide levels through Nox2 activity. These findings can help to predict the risk 
of ACT development before the start of treatment. To gain a deeper understanding, it is 
necessary to unravel the molecular mechanisms underlying this linkage. The recent 
advancement of gene-editing tools, in particular CRISPR/Cas-based techniques, made it 
feasible to delete, insert, or swap gene fragments precisely and reliably (Gasiunas et al., 
2012; Jinek et al., 2012; Cong et al., 2013). The most elegant way to determine if the above-
mentioned SNP contributes to the phenotype at all, is to correct the SNP in our ACT patient 




In our laboratory, gene editing with CRISPR/Cas9 in electroporated iPSCs has resulted in 
two iPSC lines with homozygous and ten iPSC lines with heterozygous corrections in the 
RAC2 SNP rs13058338. Separation and detailed analysis of mixed clones is likely to result in 
more iPSC lines with a SNP-corrected genotype. 
The company that provided the reagents for gene editing suggested using an HDR template 
enhancer to increase the integration frequency. We tested the HDR enhancer with two 
different concentrations, namely 20 µM and 30 µM. High concentrations of the HDR 
enhancer can be cytotoxic because it is dissolved in DMSO. Cytotoxicity was estimated by 
evaluating bright field microscopy images by cell density, amount of cell debris, and 
confluency. The HDR enhancer clearly showed a dose-dependent cytotoxic effect, which 
was greater than the stress of electroporation alone. Cell survival was less relevant than 
HDR template integration frequency, because only few cells with desired editing results are 
necessary to establish new cell lines. Therefore, it could be possible that the success rate 
was high, although fewer cells survived the procedure. 
Amplicon sequencing gave a first indication of how many homozygous edits occurred. 
Electroporation without HDR enhancer resulted in an integration frequency of 6.6%. It 
increased to 9.1% with 20 µM HDR enhancer and was at 10.0% with 30 µM HDR enhancer. 
Judging from the estimate given by amplicon sequencing, the HDR enhancer has a dose-
dependent benefit on integration frequency. 
Sanger sequencing of individual clones allowed for a more reliable assessment of integration 
frequency. This showed that the use of an HDR enhancer did in fact increase the number of 
clones with edits from six without enhancer to ten and nine with 20 µM and 30 µM HDR 
enhancer, respectively. For the majority of these edited clones (six out of ten with 20 µM, and 
six out of nine with 30 µM), Sanger sequencing results do not allow a concluding remark 
about editing success, because the results were inconclusive. This could either stem from 
mixed clones, which happens when picked colonies did not stem from one clone alone. Or 
the genotype derived from an increased number of cut-repair-cycles at the target site. To 
further investigate why so many clones show ambiguous genotypes, the clones in question 
were separated and sequenced again.  
To this point, the overall editing rate without HDR enhancer was not worse than with 
enhancer. In total, we have found two clones with a homozygous edit: one from the batch 
without HDR enhancer and one treated with 20 µM enhancer. Heterozygous edits were 
expectedly more frequent, with four clones from the preparation without HDR enhancer and 
three clones with 20 µM and 30 µM of HDR enhancer, respectively. So far, the predictions 
from the amplicon sequencing deviated greatly from our final number of clones. A reason 




predictions. Overall, amplicon sequencing can be considered a checkpoint test to see if the 
introduction of the CRISPRS/Cas9 complex occurred at all, and if the HDR was introduced 
into the genome. 
The newly established iPSC lines are currently cultured, expanded, and monitored for stable 
introduction of the HDR template. Mixed clones are separated and tested with Sanger 
sequencing. As a next step, edited iPSC lines are going to be differentiated into iPSC-CMs 
and tested for susceptibility to DOX treatment. 
6.5. Telomeres in cardiac diseases 
Recently discovered connections between telomere biology and cardiac diseases raised the 
question if telomere length is also altered in our human iPSC-CM model of ACT and if 
increased telomerase activity could rescue the ACT phenotype. In order to investigate this 
possibility, we first measured telomere length in iPSCs and iPSC-CMs from ACT and control 
patients. We found that telomeres were longer in iPSCs than in iPSC-CMs in both the ACT 
patient and control patient groups (Figure 5-14). Furthermore, we showed that the relative 
length of telomeres was shorter in ACT-iPSC-CMs compared to control patients (Figure	
5-15). These data are in line with studies showing a clear link between cardiac diseases and 
telomere length (reviewed by Martínez and Blasco, 2018). Recently, a study found that 
telomere length in leukocytes correlates with the severity of the cardiomyopathy (Chatterjee 
et al., 2018). Furthermore, telomere-related SNPs were associated with ventricular 
arrhythmias in ischemic cardiomyopathy, which suggests that telomere length and telomere 
SNPs could be used as biomarkers to predict cardiac disease predisposition, development, 
and severity (Sawhney et al., 2016, 2018; Chang and Blau, 2018). 
In ACT, a significant part of the detrimental effects of DOX is attributed to increased ROS 
production. Von Zglinicki and colleagues reported that oxidative stress shortens telomeres 
(von Zglinicki, 2002, 2006). Inversely, it was reported that high telomerase activity is 
connected to low mitochondrial H2O2 production (Beyer et al., 2016; reviewed by Quryshi et 
al., 2018), contradicting previous reports about ROS-induced mtDNA damage through 
mitochondrial hTERT (Santos et al., 2004, 2006). A role of TERT in mitochondria under 
oxidative stress is possible, because under oxidative stress, TERT is excluded from the 
nucleus and colocalizes with mitochondria (Haendeler et al., 2004, 2009). In this way, TERT 
protects human fibroblasts against oxidative stress (Ahmed et al., 2008). Compromised 
mitochondria have been linked to short telomeres (Chang et al., 2016) and telomerase 
deficiency predisposes mice to heart failure (Ait-Aissa et al., 2019). Another report showed 
an in vivo mouse model that telomerase expression protects the heart after acute MI (Bär et 
al., 2014). A tighter link between telomeric proteins and metabolic control is also possible: 




2012b). Considering that damaged mitochondria are a major source of ROS in ACT, our 
human iPSC-CM model of ACT is suitable to investigate this interaction in greater detail. 
Initial experiments showed slightly longer telomeres in iPSC-CMs from control patients than 
from ACT patients. These results are going to be backed by a larger set of measurements. In 
the meantime, we have collected three samples per ACT patient and control patient of iPSCs 
and iPSC-CMs to validate and confirm the initial results. Due to time constraints, it was not 
possible to include these results into this thesis. The samples are going to be measured by 
our collaborators Shambhabi Chatterjee and Christian Bär at the Medizinische Hochschule 
Hannover. That will allow us to estimate if the detected differences are merely aberrations 
one would expect from different cell lines, or if there is a consistent difference in telomere 
length between ACT patients and control patients. We performed a transcriptome analysis of 
ACT patient EHMs treated with 0.25 µM DOX and compared them to an untreated patient 
group. We identified DEGs that are differentially expressed specifically in the ACT patient 
group after DOX treatment, but not in control EHMs. Interestingly, GO-term analysis of DOX-
induced DEGs identified, among others, significantly increased expression of positive 
regulators of telomere maintenance in ACT-EHMs, but not in untreated controls.  
The same holds for the comparisons between iPSCs and iPSC-CMs. These results show the 
expected tendency of longer telomeres in iPSCs compared to matched iPSC-CMs, which is 
in line with reports about telomere length in iPSCs (Huang et al., 2014). These initial 
experiments suggest that iPSC-CMs from ACT patients have shorter telomeres than iPSC-
CMs from control patients, which in turn could contribute to ACT-disease development. To 
test if longer telomeres and increased TERT expression can ameliorate DOX-induced 
detrimental effects on iPSC-CMs, we transduced our cells with AAV6-TERT vectors. 
6.6. Overexpression of TERT with AAV vectors 
Although telomere length in our iPSC-CMs has not been definitively determined, TERT 
overexpression could exert protective effects, because some of the beneficial effects of 
TERT activation were observed unrelated to telomere length (Ahmed et al., 2008). Protocols 
for AAV6-mediated TERT transduction in mice were established in the laboratory of Dr. 
Christian Bär at the Medizinische Hochschule Hannover and adapted to iPSC-CMs in our 
group. We used AAV6-GFP vectors to test transduction and determine the optimal MOI in 
our model. Due to limited vector and iPSC-CM availability, TERT expression in iPSC-CMs 
was not confirmed directly after transduction, which is a limitation. Nevertheless, expression 
levels of TERT in transduced iPSC-CMs were analyzed in Hannover and showed a 15-fold 
overexpression with an MOI of 1 x 104 (unpublished data, Shambhabi Chatterjee, personal 
communication). Positive GFP signals indicated that gene delivery with AAV6 vectors and 




an MOI of 1 x 103 for 48 h. Immediately after AAV6 transduction, iPSC-CMs were treated for 
three days with 0.25 µM DOX and 1 µM DOX. Subsequent apoptosis analysis showed that 
vector transduction itself induced apoptosis even in DOX-untreated iPSC-CMs (Figure 5-18). 
Apoptosis rates were 2.5- to 3.5-fold higher in AAV6-treated iPSC-CMs compared to AAV6-
untreated controls. DOX treatment increased apoptosis rates slightly more. To minimize the 
influence of AAV6 treatment on apoptosis rates, iPSC-CMs were given a recovery period of 
seven days before the start of DOX treatment (Figure 5-19D). Additionally, the DOX 
concentration was set to 0.5 µM. With these optimized treatment conditions, AAV6 
transduced cells without DOX treatment had the same apoptosis rate of approximately 15% 
as untreated cells (Figure 5-19B). Unexpectedly, AAV6-TERT transduced iPSC-CMs did not 
show decreased apoptosis rates after DOX compared to empty AAV6-treated controls 
(Figure 5-19). Assessment of ROS production with an Amplex red assay also showed no 
effect on ROS production after AAV6 TERT transduction compared to the empty AAV6 
control. The result was in line with the results from our apoptosis assay, but may be contrary 
to previous reports about reduced oxidative stress through TERT activation (reviewed by 
Quryshi et al., 2018). To validate our approach in the future, TERT expression and 
telomerase activation in iPSC-CMs after AAV6 need to be examined. All experiments were 
performed with an AAV6 vector containing a CMV promoter. To make the approach more 
specific for cardiac cells, AAV6 vectors with a cTnT promoter were produced and will be 
tested shortly in our ACT model. Besides, the O2 content of 20% in our incubators could be 
source of constant oxidative stress for iPSC-CMs. Reduction of the O2 content to 5% resulted 
in greater effect of DOX treatment on apoptosis rates (Dr. Christian Bär, personal 
communication). 
Apoptosis and ROS production appear as results of a plethora of molecular interactions. To 
confidently assess the impact of TERT activation, it could be advantageous to choose a 
more direct readout of TERT performance. In the setting of DOX-treated iPSC-CMs, where 
we expect oxidative stress, mitochondrial function and/or mitochondrial ROS production 
would be a promising readout. Mitochondrial function can be assessed with a mito stress test 
with an Agilent Seahorse analyzer. The fluorescent probe MitoSOX is suitable for the 
microscopic study of mitochondrial ROS production. In this study, the MitoSOX assay was 
established for DOX-treated iPSC-CMs. Preliminary data show that the dynamic MitoSOX 
probe can detect DOX-induced increases of mitochondrial ROS in iPSC-CMs. In future 
experiments, the probe can be used to test compounds and treatment for their mitochondrial 
ROS-reducing properties in iPSC-CMs. 
The suitability of TERT activation as a method to reduce side effects of cancer treatment is 
highly debated (Ling et al., 2012; Yan et al., 2015; Bär and Thum, 2017; Lipinska et al., 2017; 




established. hTERT translocation from nuclei to mitochondria is increased in multidrug-
resistant hepatocellular carcinoma cells, which manifested in a protective effect for 
carcinoma cells (Ling et al., 2012; Yan et al., 2015). Reduced expression of telomerase in 
cancer cells increased their sensitivity to anticancer drugs such as DOX, cisplatin, and 5-
fluorouracil (reviewed by Lipinska et al., 2017). To rebut these concerns, Muñoz-Lorente et 
al. (2018) showed that AAV9-mediated telomerase activation did not increase the K-Ras-
driven speed of lung cancer development in mice. In a viewpoint article, Bär and Thum 
(2017) provoke with the hypothesis that even in a cancer setting, the benefits of TERT 
activation would outperform its potential risks. In light of recent success rates of anti-cancer 
treatment and the increase in cancer survivors with severe long-term side effects, the 
potential of treatment options that ameliorate side effects should not be ostracized due to 
unfounded risk evaluations. Nevertheless, each case should be carefully assessed regarding 
relevant factors such as cancer type, classes of anti-cancer drugs, TERT expression of 
cancer cells, and the patient’s predisposition to side effects. 
6.7. DCM cell size 
DCM can occur in a mixed form with HCM. Both diseases lead to similar symptoms that can 
include shortness of breath, leg swelling, and tiredness (Elliott, 2000; Japp et al., 2016). 
These symptoms stem from the heart’s inability to pump blood efficiently. In DCM, stretched 
muscle fibers and a thinned ventricle wall of the left ventricle cause these symptoms. In 
HCM, the walls of the heart become stiffer because they thicken. On a cellular level these 
two forms of cardiomyopathy can be distinguished by the size of cardiomyocytes (Brodehl et 
al., 2019).  
Data sets in our lab from DCM patients with different genomic predisposition for the disease 
indicate that iPSC-CMs from DCM patients can differ greatly in size compared to healthy 
controls. Investigating the two DCM patients used in this study, we observed significantly 
smaller iPSC-CMs from DCM patient 1 compared to healthy controls and DCM patient 3 
(Figure 5-25). iPSC-CMs of HCM lines usually show increased CM size (Eschenhagen and 
Carrier, 2019). DCM patient 1 presented with a severe case of sudden DCM. The 
extraordinarily small cell size could be due to a high level of sarcomeric disarray that could 
render the cell incapable of maintaining a larger scaffold (see section 6.8). iPSC-CMs from 
DCM patient 3 were significantly larger compared to iPSC-CMs from DCM patient 1 and 
healthy control (Figure 5-25). iPSC-CM size experiments were performed in 3D with a CASY 
cell counter. iPSC-CMs were measured after ten or eleven days on culture plates. Longer or 
shorter culture periods did have an effect on the measured cell sizes (data not shown). If the 





6.8. Sarcomeric regularity 
Sarcomeres are crucial elements for the function of cardiomyocytes because they provide 
the structural backbone without which contraction of the cells, and therefore the main 
function of the entire organ, would not be feasible. Therefore, the morphological assessment 
of sarcomeric integrity can be used to estimate the functional impairment caused by the 
respective phenotype. 
A previous dissertation from our laboratory has addressed the impact of DOX on the 
sarcomeric regularity of iPSC-CMs from the ACT cohort that was also used for this study 
(Haupt, 2018). iPSC-CMs from ACT patients are more impaired by DOX-induced sarcomeric 
irregularity compared to iPSC-CMs from control patients (Haupt, 2018). ACT and DCM share 
a similar phenotype and largely only differ in the trigger of the disease. Therefore, we were 
interested if effects of DOX on the sarcomere are universal in diseased iPSC-CMs, or if the 
susceptibility is specific to ACT-iPSC-CMs. Comparing iPSC-CMs from healthy individuals in 
this study to control patients from the ACT cohort, we found that sarcomeric decay after DOX 
treatment was comparable between the control groups with a slight dose-dependent 
decrease seen in both. We expected that DOX treatment would have a detrimental effect on 
the sarcomeres in CMs from healthy donors, because of earlier published studies, where it 
has been reported that DOX treatment leads to inhibition of myofilament gene transcription, 
and sarcomere disarray through inhibition of cardiac ankyrin repeat protein (CARP) 
transcription and subsequent depletion of CARP protein levels in rat cardiomyocytes (Chen 
et al., 2012a). Furthermore, it has been shown that DOX induces calpain-dependent titin 
proteolysis (Lim et al., 2004). One prominent effect of DOX is the elevation of cellular ROS 
levels. Under oxidative stress, ROS induces irreversible protein carbonylation (Levine et al., 
1994). Carbonylation leads to depletion of crucial cellular proteins by tagging them for 
proteasomal degradation (Nyström, 2005). The amino acid residues lysine, arginine, proline, 
and threonine are particularly susceptible to carbonylation under oxidative stress (Amici et 
al., 1989; Stadtman, 1990). These four amino acids make up 25.6% of the cardiac myosin 
binding protein C (MYBPC), which has been described as selectively carbonylated during 
toxicity (Aryal et al., 2014). In our work, next generation sequencing data from 3D EHMs 
generated from ACT or control-iPSC-CMs showed that MYBPC3 was one of the genes that 
encodes for structural proteins that were down-regulated after DOX treatment. MYBPC3 is 
not only important for the function of striated muscle, but is also involved in its regulation, 
which makes it an interesting target for future studies (Gautel et al., 1995). Besides 
MYBPC3, our unpublished transcriptomic data show significant decreases in components of 
the actin cytoskeleton (18.03%, e.g. ACTA2, MYBPC3, MYH6, MYH7, MYL2, MYL7, TNNI3, 
TNNT2), and muscle contraction (8.75%, e.g. LDB3, MYBPC3, MYH6, MYL2, MYOM1, 




studies on protein depletion, together with our results on specific gene down-regulation and 
inhibition of global mRNA translation offer an explanation on how DOX treatment and 
resulting oxidative stress can lead to sarcomeric disarray. 
An even more relevant question was to determine if we would see similar rates of sarcomeric 
degradation after DOX treatment in iPSC-CM from ACT patients and DCM patients. In our 
study, the decrease of sarcomeric regularity in iPSC-CMs from DCM patients was minimal 
with 0.05-fold change after treatment with 1 µM DOX (Figure 5-27B). In general, sarcomeric 
regularity in these DCM-iPSC-CMs was very low and deviated significantly from healthy 
iPSC-CMs. This is in line with frequent mutations in genes encoding for sarcomeric proteins 
in DCM patients (reviewed by Chang and Potter, 2005; Morimoto, 2008). Due to the very low 
values for sarcomeric regularity in the DCM group at baseline, the reduction following DOX 
treatment was not as strong as observed in cells from the ACT cohort. Considering the 
immunofluorescence images of the DCM-iPSC-CMs, it can be concluded that the patient 
iPSC-CMs from our DCM cohort are damaged to a higher degree at baseline than the ones 
from our ACT cohort. Increased heterogeneity in sarcomeric organization of iPSC-CMs of 
DCM patients has been reported previously (Sun et al., 2012). This conclusion is supported 
by the fact that the trigger for the DCM phenotype could be genetic in 30% of the cases and 
therefore inherent, while ACT only occurs after an external trigger, namely DOX treatment. 
Until now it has not been finally determined whether the used ACT- and DCM-patient’s 
iPSCs have a genetic predisposition to the later disease. However, a decrease in sarcomeric 
regularity through DOX treatment and oxidative stress does not seem to be exclusive to 
ACT. Oxidative stress regulates proteolytic pathways, leading to a decrease of structural 
proteins, which has also been described in other disease settings, such as muscle atrophy in 
disuse atrophy (Powers et al., 2005). A recent review of multiple iPSC-CM studies on DCM 
concluded that sarcomere disorganization is a common finding in all disease lines 
(Eschenhagen and Carrier, 2019). 
Taken together, the analysis of sarcomeric regularity after DOX treatment showed that 
disturbance of sarcomeric structures through DOX is a general effect of DOX treatment. 
Reduction of sarcomeric regularity in iPSC-CMs from Crt-DCM was comparable to the 
observed effect in iPSC-CMs of control patients of the ACT cohort. The very high amount of 
sarcomeric disarray in iPSC-CMs from DCM patients without DOX treatment makes it difficult 






iPSC-CMs provide a consistent way of researching cellular processes in a human setting. 
This makes them a suitable tool to study human molecular mechanisms and is hence 
advantageous over animal models. However, disease modeling with iPSC-CMs also has 
limitations. A major limitation is the lack of maturity of iPSC-CMs. Even when cultured for at 
least 60 days, characteristics of iPSC-CMs resemble more the ones of CMs at a neonatal 
state rather than adult CMs (Kolanowski et al., 2017; Yoshida and Yamanaka, 2017). While 
metabolism and calcium handling do not differ much from adult CMs, the round, multiangeled 
morphology is distinct from the characteristic rod shape of mature CMs. For each research 
question, it has to be evaluated wheather the properties of iPSC-CMs are fitting to answer 
the particular research question, especially when investigating cardiac proteins that are 
differentially expressed throughout life such as Nox2 and Nox4. A shortcoming compared to 
animal studies or tissue samples is that iPSC-CM cultures represent monocultures of one 
cell type. That neglects interactions between different cell types and cell behavior in a natural 
organism. To reduce the bias, it is recommended to use organoids that mimic the nature of 
an organ better (Hudson et al., 2019). Besides, iPSC-CMs can be used in a wide range of 
biological assays. The ability to define cell numbers, add treatments, and control the culture 
conditions has benefits over tissue samples. However, the development of iPSC lines and 
the production of iPSC-CMs are cost and labor intensive. That sets boundaries to the sample 
numbers, which in turn hamperes genomic studies with iPSC cohorts. Furthermore, the small 
sample number combined with natural occurring inter-individual genetic variability manifests 
a hurdle to data interpretation. To notice abberrations that stem for a patient’s genetic 
background, the aim was to use at least 2 different iPSC clones per person. An additional 
measure is the use of appropriate controls that match gender, age, disease history, etc. of 
the patients. In this study, there was a female patient (ACT patient 3) that did not have a 
matched female control (see section 3.1). In future studies it would be best to use isogenic 
controls that were created with gene editing (Figure	2-2). 
Overall, iPSC-CMs are a valuable tool to research human disease mechanisms on a cellular 
level. Being aware of and managing the limitations of this model secured consistent and 




8. Conclusion and outlook 
This study addressed a broad range of ACT-related topics, from subcellular drug distribution 
over risk factor validation to emerging therapies to overcome ACT in the clinic. In this way, it 
displays the versatile options the iPSC model offers to investigate cardiac diseases. 
Especially in combination with CRISPR/Cas9, human iPSC models benefit the research on 
disease-associated mutations, risk assessment, and drug screening. 
While we described for the first time intracellular levels of DOX and distribution thereof in 
iPSC-CMs, we also presented a protocol for measurement of intracellular DOX content with 
HPLC. This protocol could be adjusted to work with other cellular samples and tissues, and 
hence be applied in future molecular or clinical studies of ACT. 
Currently, we are working on characterizing and validating the CRISPR/Cas9-edited iPSC 
lines. Moving forward, tests with iPSC-CMs from these isogenic iPSC lines on susceptibility 
towards DOX-induced sarcomeric damage, ROS production, and changes in calcium 
handling will reveal the impact of the described SNP on disease development. In this way, 
other ACT-associated SNPs can be tested for their relevance and the molecular mechanisms 
behind the clinical correlation can be revealed. 
iPSC-CMs offer a platform to screen cardioprotective drugs like ranolazine or dexrazoxane in 
a human in vitro setting. The possibility to try different ratios of DOX and adjuvant drug 
makes it very versatile and the use of human patient-specific iPSC-CMs gives high relevance 
to the approach. 
In the following months, we, together with our collaborators, will measure telomere length in 
a large set of generated iPSCs and iPSC-CMs from ACT and DCM patients. This will be the 
basis for assessments of telomere status in our models and potential involvements of 
telomere dysregulation in the specific patient disease history. Furthermore, we will continue 
to optimize in vitro TERT overexpression in iPSC-CMs to evaluate its utility as a potential 
treatment for ACT or cardiomyopathies in general. 
A remaining question is in which way and through which pathways DOX exposure influences 
global mRNA translation. To better understand ROS production and ROS signaling in ACT, it 
is promising to investigate the crosstalk between Nox2 and mitochondria, both of which are 
key ROS producers. Gaining a deeper understanding of the exact interactions on the 
molecular level is crucial for specific interventions on ACT.  
In cardiac research, disease modelling with human iPSCs is a valuable tool to discover 
molecular mechanisms, validate results from animal experiments and confirm data from 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































Detailed values of statistical analyses 
	





5-1B ACT untr. vs ACT 




-0.9916 -1.015 to -0.9677 
<0.001 
5-1B ACT 1 µM DOX vs 




-3.719 -6.195 to -1.243 
0.02 
5-1B ACT 5 µM DOX vs 




-3.519 -4.660 to -2.378 
<0.001 
5-2A Control untr. vs 




-17465 -27490 to -7440 0.0105 
5-2A Control untr. vs 




-29841 -54106 to -5576 0.0283 





0.9935 0.9708 to 1.016 
<0.001 
5-2B Control untr. vs 




0.9862 0.9248 to 1.048 
<0.001 
5-3C ACT 0 vs ACT 7 Two-way ANOVA/ 
mixed effects 
Tukey 
0.8268 0.3199 to 1.334 
0.0132 





0.7491 0.2138 to 1.284 0.0262 





0.9704 0.8962 to 1.045 <0.001 
5-4A Mito vs. membrane 
fraction 
Two-way ANOVA Tukey 
164608 4004 to 325212 
0.04 
5-6C ACT untr. vs ACT 
1 µM DOX 





5-6C Control untr. vs  
control 1 µM DOX 





5-6D Untreated vs. 1 µM 
DOX 
Two-way ANOVA n/a 0.2205 0.08777 to 
0.3532 
0.005 




n/a -0.2237 ± 
0.06419 
-0.3808 to 0.0666 0.01 




n/a -2494 ± 
815.5 
-4423 to -566.0 0.02 
5-20A Blank untr. vs 
blank 0.5 µM DOX 




5-20A Empty AAV6 untr. 
vs 
Empty AAV6 
0.5 µM DOX 




5-20A AAV6 TERT untr. 
vs 
AAV6 TERT 
0.5 µM DOX 




5-20B Blank untr. vs 
blank 0.5 µM DOX 




5-20B Empty AAV6 untr. 
vs 
Empty AAV6 
0.5 µM DOX 




5-20B AAV6 TERT untr. 
vs 
AAV6 TERT 
0.5 µM DOX 






CRT 1 vs DCM 1 One-way ANOVA Tukey 
2535 2125 to 2944 <0.001 
5-25B 
Volume 
CRT 1 vs DCM 3 One-way ANOVA Tukey 
-811.1 -1221 to -401.2 <0.001 
5-25B 
Volume 
DCM 1 vs DCM 3 One-way ANOVA Tukey 
-3346 -3712 to -2979 <0.001 
5-25B 
Diameter 
CRT 1 vs DCM 1 One-way ANOVA Tukey 
2.713 2.287 to 3.138 <0.001 






CRT 1 vs DCM 3 One-way ANOVA Tukey 
-0.7417 -1.167 to -0.3162 <0.001 
5-25B 
Diameter 
DCM 1 vs DCM 3 One-way ANOVA Tukey 
-3.454 -3.835 to -3.074 <0.001 
5-27A DCM 3. 0.25 µM 
DOX vs DCM 3. 
1 µM DOX 





5-27C Crt-DCM 2. untr. vs 
DCM 1. untr. 
One-way ANOVA Tukey 
7.442 5.845 to 9.040 <0.001 
5-27C Crt-DCM 2 untr. vs 
DCM 3 untr. 
One-way ANOVA Tukey 
8.580 6.971 to 10.19 <0.001 
5-27C Crt-DCM 2. 
0.25 µM DOX vs 
DCM 1. 0.25 µM 
DOX 
One-way ANOVA Tukey 
6.569 4.871 to 8.267 <0.001 
5-27C Crt-DCM 2. 
0.25 µM DOX vs 
DCM 3. 0.25 µM 
DOX 
One-way ANOVA Tukey 
7.573 5.871 to 9.275 <0.001 
5-27C Crt-DCM 2. 1 µM 
DOX vs 
DCM 1. 1 µM DOX 
One-way ANOVA Tukey 
5.943 4.277 to 7.609 <0.001 
5-27C Crt-DCM 2. 1 µM 
DOX vs 
DCM 3. 1 µM DOX 
One-way ANOVA Tukey 
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